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BSP              bromosulfophthalein 
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Fig.  figure 
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Renal cancer cell carcinoma (RCC) is usually chemoresistant. This 
chemoresistance would be overcome when a cytostatic is applied for which the 
RCC possesses an uptake transporter. In the present study I investigated the 
expression of solute carrier (SLC) transporters in different RCC samples and 
their ability to interact with chemotherapeutical drugs. I tested five RCC cancer 
lines as well as normal and tumor renal tissue for the expression of different 
SLC by RT-PCR and TaqMan real-time PCR. In two of five RCC lines, A498 
and 786-O, I observed a highly significant expression of SLC22A3 (hOCT3). 
The uptake of the organic cation [3H]MPP (4-methyl-pyridinium iodide) into 
these cells and also into hOCT3 stably transfected CHO cells was inhibited by 
irinotecan, vincristine and melphalan. The Ki values determined from Dixon 
plots for irinotekan and vincristine ware 1.72±0.45 µM, 17±4.81 µM, and 
366±51µM, respectively.  The cytotoxic activities of the selected drugs were 
tested by the [3H]thymidine incorporation and MTT assays on CHO-hOCT3, 
A498 (high expression of hOCT3)  and ACHN cell lines (low expression of 
hOCT3). The growth of CHO-hOCT3 was inhibited by 20% more with irinotekan 
and by 50% more with vincristine compared to non-transfected CHO cells.  
Melphalan produced 20-30% more inhibition in hOCT3 expressing cells 
compared to non-expressing control cells. Similar results were obtained for 
A498 and ACHN cells. Thus, my data support the hypothesis that the sensitivity 
of tumor cells to chemotherapeutical treatment depends on the expression of 










Nierenzellkarzinome (RCC) sind normalerweise Chemotherapie-resistent. Diese 
Chemoresistenz kann durch Gabe von Zytostatika überwunden werden, für 
welches die Karzinomazellen einen Aufnahmetransporter exprimieren. 
In der vorliegenden Arbeit wurde sowohl die Expression unterschiedlicher 
löslichen Carrier Transporter (SLC) in verschiedenen RCC-Proben als auch ihre 
Fähigkeit, mit verschieden Chemotherapeutika zu interagieren, untersucht. 
Dafür wurden fünf Nierenkarzinoma-Linien, gesundes Gewebe und 
Nierentumorgewebe mittels RT-PCR und TaqMan real-time-PCR analysiert. In 
zwei der untersuchten Zelllinien, A498 und 786-O, konnte eine signifikant 
erhöhte Expression von SLC22A3 (hOCT3) detektiert werden. Die Aufnahme 
des organischen Kations [3H]MPP (4-Methylpyrididium-Iodid) in diese Zellen 
und in stabil transfizierte hOCT3-exprimierende CHO-Zellen (CHO-hOCT3) 
wurde durch die Agenzien Irinotekan, Vincristin und Mephalan inhibiert. Die 
durch Dixon-Plots bestimmten Ki-Werte für Irinotekan und Vincristin und 
Mephalan sind 1,72±0,45 µM, 17,0±4,81 µM und 366,0±51,0 µM. Die 
zytotoxischen Aktivitäten dieser Drogen wurden durch [3H]-Thymidin-
Inkorporation und MTT-Assays in CHO-hOCT3, A498 (hohe Expression von 
hOCT3) und ACHN (niedrige Expression von hOCT3) Zellen überprüft. Das 
Wachstum der CHO-hOCT3 Zellen wurde im Vergleich zu nicht-transfizierten 
CHO Zellen durch Irinotekan um 20% und durch Vincristin um 50% inhibiert. 
Mephalan löste eine 20-30%ige Wachstumsinhibierung in hOCT3 transfizierten 
im Vergleich zu nicht-transfizierten Zellen aus. Ähnliche Ergebnisse wurden für 
A498 und ACHN Zellen erhalten. Damit unterstützen die in dieser Arbeit 
erhaltenen Daten die Hypothese, wonach die Sensitivität von Tumorzellen für 
Chemotherapeutika von der Expression von Transporter-Proteinen abhängig 





1.1 Renal carcinoma cells  
 
Renal cell carcinoma (RCC) are relatively rare tumors, amounting to 
approximately 3% of all neoplastic diseases, but their incidence is steadily 
increasing [1]. In 2001, 31,000 cases of RCC were diagnosed in the U.S., and 
12,000 patients died of renal cancer [1, 2]. If locally restricted, the therapy of 
choice is surgical removal of the tumor-bearing kidney, leading to complete 
restoration of the patient. In the presence of metastases, however, surgery is no 
longer feasible. Unfortunately, most RCC and metastases are chemoresistant, 
i.e. they cannot be treated successfully by cytostatics [1]. One third up to one 
half of the patients has metastases at the time of diagnosis and, due to the 
chemoresistance, a mean survival time of 7 to 11 months only. 
Seventy to eighty percent of RCC are clear cell carcinoma [3]. The name is 
based on the bright appearance of these glycogen-storing cells in the light 
microscope. Most of these cells show a mutation of the von Hippel-Lindau (vHL) 
gene. The vHL gene codes for a protein that leads to the faster degradation of 
hypoxia-induced factor HIF-1α [4]. Loss-of-function mutations of the vHL gene 
cause an abnormally high activity of HIF-1α which, among other effects, leads 
to a strong vascularisation of the tumor. Ten to fifteen percent of RCC are of the 
papillary type, five percent of the chromophobe type, and 3-5% are renal 
oncocytoma [3]. Clear cell carcinoma and papillary carcinoma are derived from 
proximal renal tubules. 
The proximal tubules are the first segment of nephron, which is reached by the 
ultrafiltrate. In proximal tubules, all organic solutes such as glucose, amino 
acids, and mono- and dicarboxylates are reclaimed to avoid their loss which the 
urine. Two thirds of NaCl and water, i.e. 120 liters per day, are reabsorbed. In 
addition, proximal tubules secrete endogenous waste product as well as a large 
number of exogenous compounds such as drugs and toxins. It appears, 
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therefore, appropriate to state that proximal tubules are the “working horses” of 
the kidney. 
To accomplish the secretion of anionic and cationic drugs and toxins, the 
epithelial cells of proximal tubules are equipped with a number of transporters in 
the basolateral and apical membranes [5]. The transporters in the basolateral 
membrane are involved in the first step of secretion, the uptake of organic 
anions and cations from the blood into the tubule cell. The transporters in the 
apical membrane release the organic anions and cations into the urine. The 
organic anion transporters 1 and 3 (OAT1 and OAT3) are located in the 
basolateral membrane of proximal tubule cells, and take up organic anions in 
exchange for intracellular α-ketoglutarate. Many widely used drugs such as 
penicillines, diuretics, ACE inhibitors, analgetics, and uricosurics interact with 
OAT1 and OAT3. The organic cation transporters 1-3 (OCT1, OCT2, OCT3) are 
also located in the basolateral membrane and take up organic cations from 
blood into the proximal tubule cells [6]. Again, several widely used drugs are 
transported by the OCTs, such as histamine receptor blockers, adrenergic 
receptor agonist and antagonist, dopamine antagonists, and others. OATs and 
OCTs belong to the same transporter family, the solute carrier (SLC) family 22. 
The apical (luminal, brush-border) membrane of proximal tubule cells is 
equipped with a number of transporters for the release or uptake of organic 
anions and cations [5]. The voltage-driven transporter OATv1, the organic 
anions antiporter OAT4, and the ATP-driven multidrug resistance-related 
proteins MRP2 and MRP4 play a major role in organic anion release from the 
cells. Other transporters such as URAT1, OAT-K1 and OAT-K2 may be 
involved in organic anion absorption. The release of organic cations across the 
apical membrane occurs by exchange against luminal protons and is performed 
by the multidrug and extrusion transporter 1 (MATE1) [7]. Alternatively, organic 
cations can be transported out of proximal tubules cells by P-glycoprotein alias 
multidrug resistance transporter 1 (MDR1), an ATP-driven transporter residing 
in the apical membrane. 
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The expression of MDR1, MRP2 and MRP4 in cancer cells causes a resistance 
to several cytostatic drugs. Since most renal tumors originate from proximal 
tubule calls, they may have “inherited” these multidrug resistance transporters 
from their progenitor cells, rendering RCC and metastases chemoresistant. It is 
not known, whether RCC still express some other transporters typical of 
proximal tubule cells. Since the OAT and OCT transporters are polyspecific, i.e. 
they interact with a huge number of chemically unrelated compounds, it may 
well be that these transporters could be used to direct cytostatic drugs into the 
cancer cells. Indeed, some of the proximal tubular transporters interacted with 
methotrexate, nucleoside analogs, and cisplatin (for review see Table 1.1)     
 
1.2 Transporter characterization  
1.2.1 The SLC transporter superfamily 
1.2.1.1 The amino acid transporter family SLC7 
 
The SLC7 family is divided into two subgroups, the cationic amino acid 
transporter CAT (SLC7A1-4) and the glycoprotein-associated amino acid 
transporters graAT (SLC7A5-11). Structurally, glycoprotein-associated amino-
acid transporters consist of the heterodimeric amino acid transporter (HAT) or 
catalytic chain and the associated glycoprotein (heavy chain) 4F2hc (CD98) or 
rBAT. The heavy chain is covalently and hydrophobically associated with the 
catalytic chain [30]. Only upon association, activity is observed.  The cationic 
amino acid transporter subfamilies have 14 transmembrane segments, some of 
which are glycosylated. The CAT subfamily transporters are 20% identical and 




Protein Name Human Gene 
Name 
Interaction with cytostatics  Reference  
OAT1 SLC22A6 Methotrexate, Cisplatin [8] 
OAT2 SLC22A7 Methotrexate [8] 
OAT3 SLC22A8 Methotrexate [8] 
OAT4 SLC22A11 Methotrexate [9, 10] 
OCT2 SLC22A2 Cisplatin [9, 11] 
OCT6 SLC22A16 Doxorubicine, Epirubicine [12] 
OATP-A SLC21A2 Bamet-UD2 and Bamet-R2 [9, 13, 14] 
OATP-C SLC21A6  Irinotekan metabolite [9, 13-15] 
OATP-D SLCO21A11 Methotrexate [10, 14, 16] 
CNT1 SLC28A1 Gemcitabine, 5’-fluorouridine, 
Cytarabin 
[17] 
CNT2 SLC28A2 Anthracyclines Pirarubicin, 
Doxorubicine 
[17-19] 
CNT3 SLC28A3 Gemcitabine, Fludarabine, 
Cladribine 
[17, 20] 
ENT1  SLC29A1 Gemcitabine, Fludarabine, 
Cladribine, Cytarabine 
[18, 21] 
ENT2  SLC29A2 Gemcitabine, Fludarabine, 
Cladribine, Cytarabine 
[18, 21] 
LAT1 SLC7A5  Melphalan [22-24] 
MCT1 SLC16A1 Iphosphamide [25, 26] 
MCT2 SLC16A2 Iphosphamide [25-27] 
RFT SLC19A1 Methotrexate [28, 29] 
ThTr SLC19A2 Methotrexate [28, 29] 





Main substrates of CAT subfamily transporters are positively charged amino 
acid such as L-arginine, L-lysine, L-histidine etc. Cationic amino acid 
transporters mainly exchange cationic L-amino acids with intracellular amino 
acids such L-alanine, L-leucine, and the most pronounced trans-stimulation was 
observed for CAT-1 [32]. CAT transportersare expressed ubiquitously except for 
liver tissue. Their expression site is the basolateral membrane of epithelial cells 
[33]. The subfamily graAT transporters have 12 transmembrane segments, and 
the catalytic domain is not glycosylated [31].  The graAT transporters mainly 
function as exchangers, but the affinity to intracellular L-amino acids such L-
leucine, L-cysteine is low. The main members of graAT transporters are the L-
amino acid transporter 1 and 2 (SLC7A5, SLC7A8). The hLAT1 is widely 
expressed in human body, but the first cDNA was obtained from human 
leukocytes. LAT1 mainly functions as an exchanger with a ratio of 1:1, preferred 
efflux substrates of LAT1 are L-leucine, L-isoleucine, and L-methionine. For 
influx, LAT1 mostly uses aromatic amino acids [34]. LAT2 (SLC7A8) is 
ubiquitously expressed in the human body; main sites are kidney proximal 
tubules at the basolateral membrane. Functionally, LAT2 exchanges neutral L-
amino acids across the basolateral membrane and equilibrates their 
concentration inside cells. LAT2 shows similar functional activities as LAT1. 
LAT1 and LAT2 were reported to interact with the mustard derivates of L-
phenylalanine, melphalan [35].            
  
1.2.1.2 The sodium dicarboxylate transporter family SLC13 
 
The SLC13 transporters include two major subgroups, Na+-sulphate co-
transporter (NaS) and Na+-carboxylate (NaC) co-transporters. This transporters 
family is widely present in variety of organs. The members of the SLC13 group 
consist of 8-13 transmembrane helices and both subgroups have comparable 
amino acid sequences (similarity 66-70%) [36]. SLC13 group transporters 
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function as symporters using the Na+ ion gradient as energy. The ratio between 
Na+ ions and substrate is equal to 3:1. The subgroup of NaS includes NaS1 and 
NaS2 in humans. The main substrates are sulphate, thiosulphate, and selenate 
ions. The hNaS1 mRNA was detected in kidneys, ileum, duodenum/jejunum, 
and colon [37]. The hNaS2 is mainly present in placenta, heart, and testis [38]. 
The main function of NaS transporters is sulphate absorption. The second 
subgroup includes hNaC1 and hNaC3. Main substrates for this group are 
dicarboxylates such as α-ketoglutarate, succinate, and citrate etc. hNaC1 is 
mainly expressed in kidneys and intestine [39]. hNaC3 is expressed in brain, 
kidneys, liver, and lung. The main function of hNaC1 and NaC3 is the transport 
of Krebs cycle intermediates. An other function of these transporters is to 
organize the dicarboxylate gradient in kidney tubule cells, which is used as 
energy source for other transporters (OATs) [8]. Interactions with cytostatics are 
not known for this transporter group. 
 
1.2.1.3 The monocarboxylate transporter family SLC16 
 
The monocarboxylate co-transporter (MCT) includes 14 members, four of which 
(MCT1-4) show proton dependent monocarboxylate transport. Structurally, MCT 
transporters consist of 12 transmembrane helices. For expression of a 
functional protein at the plasma membrane, MCT1-4 need the monotopic 
ancillary protein CD147 [40]. Main substrates for MCT family transporters are 
monocarboxylate ions such as L-lactate, propionate, pyruvate, acetate etc. 
MCT1 (SLC16A1) and MCT2 (SLC16A7) are expressed ubiquitously, with a 
strong expression detected in muscle, heart, liver, and erythrocytes [41]. The 
main function is the exchange of monocarboxylates between cells and 
extracellular fluids in the human body. MCT transporters are tightly connected 
with the metabolism of glycogen. The monocarboxylate transporters mediate 




 1.2.1.4 The folate/thiamine transporter family SLC19  
 
The SLC19 transporter family includes three members: reduced folate 
transporter (RFT; SLC19A1) and two thiamine transporters ThTr1 (SLC19A2) 
and ThTr2 (SLC19A3) [28]. Structurally all three members are similar. They 
contain 12 transmembrane helices and one site for N-glycosylation. The 
SLC19A1 prefers as substrates folate analogs: N5-methytetrahydrofolate, N5-
formyltetrahydrofolate, and methotrexate. Most substrates of SLC19A1 exist as 
anions at physiological pH, and this transporter sensitive to probenecid. The 
mechanism of transport H+ symport or folate OH- antiport [42]. Transport 
investigations have shown that SLC19A1 is electroneutral. Expression of 
SLC19A1 was detected ubiquitously, but high levels were observed in kidney, 
intestine, and placenta [43]. The main function of SLC19A1 is folate 
reabsorption. RFT plays also an important role in the sensitivity to methotrexate 
analogs [44]. 
The other member of SLC19 family, ThTr1 and 2, prefer as substrates thiamine 
and thiamine derivates [45]. Transport activity investigations suggest that these 
transporters function as thiamine/H+ antiporters. SLC19A2 and SLC19A3 are 
expressed ubiquitously in the human body [28]. The main function is the 
reabsorption of thiamine. An interaction with known cytostatic agents was not 
detected. 
 
1.2.1.5 The organic anion and peptide transporter family SLC21 
 
The SLC21 transporter family includes 36 members in humans. These 
members are divided in six families from OATP1 to 6. Structurally, SLC21 
transporters are similar, they consist of 12 transmembrane helices and a large 
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extracellular domain between TM9 and 10 which contains many conserved 
cysteine residues. N-glycosylation sites were found in the extracellular loop 2 
and 5.  OATPs are sodium-independent transport systems. Their transport 
appears to be driven by antiport of negatively charged ions such as bicarbonate 
and glutathione-S-conjugates. The 36 member of SLC21 family are organized 
in 6 subfamilies from OATP1 to OATP6. Organic anion transport mediated by 
OATPs is pH dependent and electroneutral. Most of substrates which are 
transported by the OATP family are organic amphipathic anions.  
 
1.2.1.5.1 OATP1 subfamily 
 
To subfamily OATP1 belong three groups OATP1A, OATP1B, and OATP1C. 
OATP1A subfamily contains a single human member, OATP1A2 (SLC21A3). It 
is a glycoprotein with a molecular weight of 85 kDa and contains 670 residues 
[46]. OATP1A2 is expressed in liver, colon, and blood-brain barrier. In brain, the 
protein is not completely glycosylated and observed at a molecular weight of 60 
kDa. The main substrates for OATP1A2 are bile salts, BSP 
(bromosulfophthalein), steroid hormones, thyroid hormones (T3,T4), 
prostaglandin E2, ouabain, etc. Human OATP1A2 has the widest range of 
substrates compared to the OATP superfamily. OATP1A2 plays an important 
role in blood-brain barrier transport and delivery neuroactive peptides to the 
brain. In hepatocytes, OATP1A2 is present at the basolateral membrane. The 
main function is extraction of bile acids from the blood. Localization and 
substrate specificity of OATP1A2 suggests its high importance for drug 
metabolism. 
The OATP1B subfamily includes two members, OATP1B1 (SLC21A6) (OATP-
C) and OATP1B3 (SLC21A8). The cDNA for OATP1B1 was cloned from human 
liver and encodes 691 residues. OATP1B1 is expressed in hepatocytes at the 
basolateral membrane [47]. The main suggested role for OATP1B1 is the 
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hepatic clearance from blood of amphipathic organic anions. The substrate 
specificity of OATP1B1 was investigated in Xenopus laevis oocytes and stably 
expressing HEK293 cells.  Its spectrum of substrates contains bile salts, 
bilirubin, BSP (bromosulfophthalein), steroid conjugates, thyroid hormones, 
eicosanoids, cyclic peptides, drugs such as benzylpenicillin, methotrexate, 
pravastatin, and rifampicin [14]. Several polymorphisms were detected in 
OATP1B1 gene, some of which lead to functional inactivity.  The cDNA of 
OATP1B3 was cloned from human liver and encodes a 120 kDa               
protein, consisting of 702 residues. Under normal conditions, OATP1B3 is 
expressed at the basolateral site of hepatocytes. Expression of OATP1B3 was 
observed also in cancer cell lines derived from stomach, colon, pancreas, lung, 
and brain. Substrate specificity for OATP1B3 was investigated in Xenopus 
laevis oocytes and stably expressing HEK293 cells. Its spectrum of substrates 
contains bile salts, bilirubin, BSP (bromosulfophthalein), steroid conjugates, 
thyroid hormones (T3,T4), eicosanoids, cyclic peptides, drugs such as 
benzpenicillin, methotrexate, pravastatin, rifampicine and also peptides like 
cholecystokinin 8 and deltorphin II. The main function of the OATP1B3 
transporter is, like OATP1B1, blood clearance of amphipathic organic anions. 
This group contains one member OATP1C1 (OATP-F). This transporter was 
cloned from a brain cDNA library, and contains 712 amino acid residues. At the 
mRNA level, expression of OATP1C1 was detected in brain and testis (Leydig 
cells) [47]. The substrate specificity of OATP1C1 is limited. Specific substrates 
are BSP, estradiol-17β-glucuronide, and estrone-3-sulfate. OATP1C1 
possesses high affinity to T4 and rT4 (reverse tetra-iodothyronine) thyroid 
hormones. The main function of OATP1C1 could be the specific transport of 






1.2.1.5.2 OATP2 subfamily  
 
The subfamily OATP2 consists of two groups, OATP2A (SLC21A2) and 
OATP2B (SLC21A9) (OATP-B) with total of three individual genes in human.  
The OATP2A group includes human OATPA1 (PGT) (SLC21A2). The protein 
contains 643 amino acids and was cloned from a kidney library. At the mRNA 
level, OATPA1 was detected in heart, skeletal muscle, and pancreas [47]. The 
main substrates for OATPA1 are different prostaglandins and tromboxane B2. 
The main function is the transport of derivates of arachidonic acid. 
The OATP2B (OATP-B) group was isolated from human brain. Expression was 
detected in liver, spleen, placenta, lung, kidneys, heart, ovary, small intestine, 
and brain [47]. In human liver, OATP2B is specifically expressed at the 
basolateral membrane of hepatocytes.  The substrate specificity is similar to the 
OATP1 family. OATP2B transports BSP (bromosulfophthalein), estrone-3-
sulfate, dehydroepiandrosterone-sulphate (DHEAS), and PGE2.   
  
1.2.1.5.3 OATP3 subfamily 
 
This subfamily consists of a single group (OATP3A) with one human gene. This 
group contains one human gene OATP3A1, which has been isolated from a 
human kidney library. OATP3A1 protein consists of 710 amino acid residues. 
This protein is 97% similar to mouse and rat protein. OATP3A1 is expressed 
ubiquitously [47]. Expression was also detected in several cancer cell lines. 
Transport activities of OATP3A1 were investigated poorly. OATP3A1 interacted 
with estrone-3-sulfate, PGE2, and benzylpenicillin [48]. Together with the wide 
expression and interspecies homology, OATP3A1 seems to be important, but 




1.2.1.5.4 OATP4 subfamily 
 
The subfamily OATP4 consists of three groups, of which two groups, OATP4A 
and OATP4C, contain two human genes.  
The OATP4A group contains human OATP4A1 (SLC21A12) (OATP-E), which 
was cloned from kidney and brain as a 722 amino acid protein. Expression of 
OATP4A was detected at the mRNA level ubiquitously with strongest 
expression in liver, heart, placenta, and pancreas. Transport activities were 
investigated in Xenopus laevis oocytes and stably transfected HEK 293 cells. 
Main substrates include taurocholate and thyroid hormones T3 and T4 [49].  In 
addition, in stably transfected HEK293 cells the uptake of steroid conjugates, 
PGE2, and benzylpenicillin was observed.  
The OATP4C group contains human OATP4C (OATP-H) (SLC21A20), the 
sequence of which was included in the database. Functional activities are under 
investigation.  
 
1.2.1.5.5 OATP5 subfamily 
  
OATP5 subfamily consist of a  single group OATP5A with a single human gene. 
This OATP5A group contains human OATP5A1 (OATP-J) (SLC21A15), which 
has been isolated and included in database [49]. The 848 amino acid residue 






1.2.1.5.6 OATP6 subfamily 
 
The OATP6 subfamily contains four groups OATP6A, OATP6B, OATP6C, 
OATP6D, which contain genes of man, mouse and rat [14]. 
The OATP6A group contains human OATP6A1 (OATP-I) (SLC21A19), which 
has been isolated from human testis [50]. Any functional activities are not 
known. 
The OATP6B group contains rat and mouse Oatp6b1 (Slc21a16). Rat Oatp6b1 
was characterized as OATP related transporter which transports DHEAS [50]. 
Mouse Oatp6b1 is not yet characterized [51]. 
The OATP6C group contains the rat and mouse gonade-specific Oatp6c1 
(Slc21a18) transporter. Oatp6b1 is not yet characterized [51]. 
The OATP6D group contains a single mouse member, Oatp6d1 (Slc21a17). 
This gene was identified as OATP related protein, but a function is not known 
[51]. 
 
1.2.1.6 The organic anion, cation, zwitterion family SLC22 
 
This family of transporter proteins has affinity to organic anions, cations and 
zwitterions. Structurally, these proteins contain 12 transmembrane α-helical 
domains and a large extracellular loop between helix 1 and 2. SLC22 
transporter family proteins are mainly expressed in kidneys, intestine, and liver. 
In these organs they perform important transport of endogenous and 
exogenous substances. The SLC22 transporter family can use different energy 
sources for transport. Mostly they function as antiporters and can exchange 




1.2.1.6.1 The organic cation transporters 
1.2.1.6.1.1 The organic cation transporter 1 (OCT1) 
 
The active form of OCT1 (SLC22A1) has been isolated from rat, mouse, man 
and rabbit. In man and rat, different splice variants were detected [52]. In all 
species OCT1 showed a strong expression in liver. In rodents it also was 
detected in kidneys and intestine. The main site of OCT1 expression in liver is 
the basolateral membrane of hepatocytes. Preferred substances of OCT1 are 
cationic substances such as tetraethylammonium (TEA), N-methylquinine, 1-
methyl-4-phenilpyridinium (MPP), drug such as desipramine, acyclovir, 
ganciclovir, metformin, endogenous compound such as serotonin, and 
prostaglandin E2  [53].  This substrate specificity is similar to two other members 
of SLC22 family, OCT2 and OCT3, but the affinities are a different. OCT1 
transport activity can be regulated by phosphorylation, e.g. stimulated by PKC 
and PKA. The main physiological role of OCT1 is the primary excretion of 
cationic xenobiotics and drugs into bile. OCT1 interacted with cytostatic agents: 
mitoxantron, and cis-platinum derivates such as carboplatin, etc [54]. 
 
1.2.1.6.1.2 The organic cation transporter 2 (OCT2) 
 
The organic cation transporter 2 (SLC22A2) was isolated from rat, human, 
mouse, and pig. The main site of expression is in kidney, but has also been 
detected in human placenta and central nervous system (CNS) [55]. In rat and 
human, OCT2 is expressed at the basolateral membrane of renal proximal 
tubule cells [56]. The expression of OCT2 is dependent on the gender and 
different short-term stimuli. It was shown that hOCT2 is constitutively activated 
by the Ca2+/calmodulin complex and inhibited by the muscarinic receptor 
agonist carbachol. OCT2 shows a similar substrate specificity as OCT1, but 
with different affinities in some cases. Well characterized substrates for OCT2 
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are: TEA, MPP, choline, dopamine, histamine, norepinephrine, serotonin, 
amantadine, and cimetidine [57]. A change in membrane potential was detected 
in Xenopus laevis oocytes expressed rat OCT2 after perfusion with choline. The 
function of rat OCT2 can be characterized as a cation antiporter. Some studies 
on Xenopus laevis oocytes show bidirectional transport of cations [58]. The 
main role for OCT2 is the clearance of cationic xenobiotics from blood in 
kidneys. OCT2 plays also an important role in transport of neuroactive cationic 
substances in CNS [59]. OCT2 can interact with cationic cytostatics such as 
cisplatin and cisplatin derivates, and with mitoxantron [54]. Main side effects of 
cisplatin are connected with OCT2 expression sites [60]. 
 
1.2.1.6.1.3 The organic cation transporter 3 (OCT3) 
 
The organic cation transporter 3 (SLC22A3) was isolated from rat, human, and 
mouse. In human body, OCT3 is mainly expressed in kidneys, skeletal muscle, 
brain, liver, placenta, and heart [59]. In brain, OCT3 was detected by in situ 
hybridization in hippocampal and cerebellar neurons [61]. The substrate 
specificity for OCT3 is similar to that of for other members of the OCT family, 
but with different affinities for some substances. For example, OCT3 transports 
TEA, MPP, guanidine, dopamine, norepinephrine and histamine [59]. hOCT3 is 
involved in cationic drug excretion in liver and also in monoamine 
neurotransmitter transport in CNS, heart, and peripheral ganglia. For hOCT3 an 
interaction with cisplatin derivates such as carboplatin, oxaliplatin was shown 






1.2.1.6.2 The organic anion transporters   
1.2.1.6.2.1 The organic anion transporter 1 (OAT1)  
 
The organic anion transporter 1 (SLC22A8) was isolated from the human, rat, 
and flounder kidneys [8]. Differently sized transcripts were detected also in 
skeletal muscle, placenta and brain. Immunohistochemical investigation of 
OAT1 expression in human and rat kidneys revealed a strong signal at the 
basolateral membrane of renal proximal tubule cells [62, 63]. The substrate 
specificity for OAT1 isolated from different species demonstrated a wide 
selectivity for endogenous organic anions, such as cyclic nucleotides, 
prostaglandins, uric acid, as well as for drug compounds: antibiotics, non-
steroidal anti-inflammatory drugs, diuretics, cytostatics, and uricosurics drugs 
[64]. The main substrate which can be used to characterize OAT1 is p-
aminohippurat (PAH). The OAT1 is acting as organic anion antiporter. PAH 
uptake mediated by OAT1 was increased by intracellular α-ketoglutarate or 
glutarate [8]. The main function of OAT1 is the excretion of organic anions and 
xenobiotics from blood into the urine through kidney proximal tubule cells. The 
hOAT1 interacted with different antiviral drugs and methotrexate [65].  
 
1.2.1.6.2.2 The organic anion transporter 2 (OAT2) 
     
The organic anion transporter 2 (SLC22A7) was cloned as NLT in 1994 [66]. In 
1998, after re-cloning and expressing in Xenopus laevis oocytes the transporter 
specificity was analyzed [67]. The hOAT2 is expressed mainly in liver and 
kidney. In humans, OAT2 is expressed at the basolateral membrane of proximal 
tubule cells [68]. Rat OAT2 expressed in Xenopus laevis oocytes showed 
affinity to PAH, dicarboxylates, PGE2, salicylate and acetylsalicylate [67]. The 
main function of hOAT2 is uptake of organic anions into the liver cells, where 
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they may be metabolized and excreted into bile. The interaction of OAT2 with 
cytostatics is unclear. 
 
1.2.1.6.2.3 The organic anion transporter 3 (OAT3) 
 
The organic anion transporter 3 (SLC22A8) has been cloned from human, rat, 
and mouse [69]. Human OAT3 is strongly expressed in kidneys, brain, and 
skeletal muscle, In kidneys hOAT3 is located at the basolateral membrane of 
proximal tubule cells [8]. The driving force for organic anion uptake mediated by 
hOAT3 is the efflux of dicarboxylates, such as α-ketoglutarate. hOAT3 can 
transport different anionic substrates, such as PAH, estrone-3-sulfate, but also 
the week base cimetidine [8]. The main function of OAT3 is the excretion of 
organic anions from blood into urine through kidney proximal tubule cells. The 
hOAT3 can interact with different antiviral drugs and methotrexate [65].  
 
1.2.1.6.2.4 The organic anion transporter 4 (OAT4) 
 
The organic anion transporter 4 (SLC22A11) was cloned from human kidney 
[70]. The main sites of expression were detected in placenta and kidneys. In 
kidneys, OAT4 is located at the apical side of proximal tubule cells. Known 
substrates which interact with human OAT4, are estrone-3-sulfate, DEAS, 
ochratoxin A, prostaglandin E2 and F2α. The main physiological function of 
OAT4 is the re-absorption of prostaglandins, anionic drugs and xenobiotics in 
proximal tubule cells. In placenta, OAT4 can excrete organic anions from fetal 




1.2.1.7 The concentrative nucleoside transporters family SLC28    
 
The SLC28 transporter family includes three subtypes of sodium-dependent 
concentrative nucleoside transporters, CNT1 (SLC28A1), CNT2 (SLC28A2), 
and CNT3 (SLC28A3). These transporters specifically transport nucleosides 
and their analogs. The transporter family is divided into subfamilies by their 
substrate specificity: CNT1 transports only pyrimidine nucleosides, CNT2 is 
specialized on purine nucleosides, and CNT3 prefers both pyrimidine and 
purine nucleosides [71]. CNT1 is mainly expressed in epithelia. CNT2 and 
CNT3 are expressed ubiquitously. The SLC28 and SLC29 families play a 
crucial role in nucleoside transport and of nucleoside-analogs .  
 
1.2.1.7.1 The concentrative nucleoside transporter 1 (CNT1) 
 
The concentrative nucleoside transporter 1 (SLC28A1) is mainly expressed in 
epithelial tissues such as kidneys, liver, and small intestine [72]. CNT1 is mainly 
located at the apical side of epithelial cells. For transport CNT1 uses the Na+ ion 
gradient [73]. CNT1 transports natural pyrimidine nucleosides. CNT1 also 
transports a broad spectrum of pharmaceutical nucleoside analogs such 
zidovudine, lamivudine, zalcitabine, and the cytotoxic cytidine analogs: 
cytarabine and gemcitabine [71]. The main function of CNT1 is absorption of 
pyrimidine nucleosides in small intestine and primary urine in kidney.  
 
1.2.1.7.2 The concentrative nucleoside transporter 2 (CNT2)  
 
The concentrative nucleoside transporter 2 (SLC28A2) was isolated from 
human, rat, mouse, and rabbit [74]. The human transporter is 81% similar to rat, 
but has differences in substrate specificity and tissue distribution. Human CNT2 
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expression was detected in kidneys, liver, placenta, heart, brain, pancreas, 
skeletal muscle, colon, rectum, duodenum, jejunum, and ileum [75]. Rat CNT2 
expression was not detected in kidneys. CNT2 mainly transports purine analogs 
and uridine. There are few antiviral drugs transported by hCNT2, such as 
dideoxyguanosine, used for HIV treatment, and ribavirin, used for hepatitis C 
treatment [71]. The CNT2 plays an important role in purine absorption in kidney 
and intestine. Interaction between hCNT2 and cytostatic nucleoside analogs 
was not shown.  
 
1.2.1.7.3 The concentrative nucleoside transporter 3 (CNT3) 
    
 The broadly-selective concentrative nucleoside transporter 3 (SLC28A3) was 
isolated from human, and mouse. Human and mouse CNT3 are 73% similar at 
the protein level [76]. High expression of hCNT2 was found in pancreas, 
trachea, bone marrow, and mammary gland; lower levels were found in 
intestine, lung, placenta, prostate, testis, and liver. CNT3 transports a broad 
range of nucleoside analogs in a Na+-dependent manner. It was shown that 
CNT3 transports a number of anticancer nucleoside drugs including: cladribine, 
gemcitabine, FdU, 5-fluorouridine, fludarabine [71]. The main role of CNT3 is 
transport of nucleosides into cells and their absorption in kidney and intestine.   
    
1.2.1.8 The equilibrative nucleoside transporter family SLC29 
 
The equilibrative nucleoside family consists of four members ENT1, ENT2, 
ENT3, and ENT4. The best characterized are ENT1 and ENT2. All members 
exhibit the possibility to exchange nucleosides. They influence many 
physiological processes depending on nucleotides.  
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1.2.1.8.1 The equilibrative nucleoside transporter 1 (ENT1)  
 
The ENT1 (SLC29A1) was isolated from human and mouse. The human ENT1 
is 79% similar to the mouse protein [77]. ENT1 is widely expressed in human 
body. High expression levels were found in brain cortex and kidneys [78, 79]. In 
kidneys, ENT1 is present at the basolateral membrane of tubule cells. ENT1 
possesses a broad-specificity to nucleoside analogs. It was shown that ENT1 
can transport purine and pyrimidine nucleotide analogs, but was unable to 
transport uridine. ENT1 was strongly inhibited by nitrobenzylthioinosine (NBTI) 
and nitrobenzylmercaptopurine (NBMPR) (K i = 5 nM) [80]. Among them, ENT1 
can interact with the coronary vasodilatator drugs dipyridamole, dilazep and 
lidofladzine. It has a poor ability to transport the antiviral drugs 2’,3’-
dideoxycytidine (ddC) and 2’,3’-dideoxyinosine (ddI) [81]. Among cytostatics, 
ENT1 mediated transport of gemcitabine, cladribine, cytarabine, fludarabine, 
capecitabine [82]. 
 
1.2.1.8.2 Equilibrative nucleoside transporter 2 (ENT2)  
 
The ENT2 (SLC29A2) is a 456 amino acid residue protein cloned from human, 
mouse and rat. Human ENT2 is 46% identical to hENT1 [83]. There are two 
splice variants of hENT2. The first is a 326 amino acid residues truncated 
protein which lacks exon 4 [84]. The second splice variant has a 40 nucleotides 
deletion in exon 9 [85]. Both splice variants are coding for a non-active 
transporter. ENT2 mRNA was detected in a wide range of tissues including 
brain, heart, placenta, thymus, pancreas, prostate, and kidneys, but in skeletal 
muscle ENT2 was not present [85]. ENT2 transports a broad range of purine 
and pyrimidine nucleosides, except of inosine [83]. In comparison to ENT1, 
ENT2 has lower affinities and turnover for the some nucleoside substrates. With 
regards to drugs, ENT2 show high affinity to AZT, ddI, and ddC [81]. From 
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cytostatics ENT2 transports gemcitabine, cladribine, cytarabine, fludarabine, 
and capecitabine [82]. 
 
1.2.1.8.3 Equilibrative nucleoside transporter 3 (ENT3)  
 
Human ENT3 (SLC29A3) is a 475 amino acid residue protein with 29% 
similarity in sequence to hENT1 [86]. hENT3 has a 51 hydrophobic amino acid 
residues long N-terminus, which is absent in ENT1 and 2. This N-terminal tail 
consists of two leucine motifs which respond for protein sorting in the Golgi 
apparatus [86]. ENT3 is present also in the cell membrane. Functionally ENT3 
is characterized poorly. ENT3 mRNA was detected in a wide range of tissues, 
but particularly abundant in placenta [86].  
 
1.2.2 The ABC transporter superfamily   
 
The ABC transporter superfamily proteins are widely present in living world. The 
coding sequences with similar structures were isolated from many organisms: 
bacteria, yeasts, fungi, insects, and vertebrata. They transport structurally 
different chemical substances, nutrients, and waste. The characteristic 
structural element of ABC transporters is the ATP binding cassette. The 
structure of most of members consists of two ABC domains. These domains 
play an important role in recognition of ATP. For their function, ABC 
transporters undergo conformational changes supported by the energy of the 
hydrolysis of the γ-phosphate ATP. This gives some advantages: transport can 
be provided against a concentrative gradient of substrate, and it is not 
dependent on membrane potential. In human body, ABC transporters are 
mainly used for xenobiotic excretion. The ABC transporters are an important 
object in pharmacology, because of their interaction with many drugs and 
influence on their activity. In oncology, ABC transporters are a opposition 
chemotherapy. Information about expression and substrate specificity for ABC 
transporters expressed in human body is presented in Table 1.2 (Addition 1) 
[87].   
    
1.3 Antitumor drug characteristics 
 
Historically, the usages of harmful chemical substances as treatment for cancer 
disease start almost half a century ago. In Bari, an accident with mustard gas 
happened in 1943. The investigation of exposed civilians showed drastical 
changes in blood count: the white cells were decreased. This finding forced 
investigators to use mustard gas as a treatment of Hodgkin’s lymphoma.  In 
nowadays chemotherapy the list of drugs includes around 100 different 
cytostatic agents. In scheme 1.1 is presented a short classification of cytostatic 























 Scheme 1.1 Classification of cytostatic drugs by their biological activities 
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1.3.1 Cytostatics acting on DNA 
1.3.1.1 Mustard analogs 
 
Mustard analogs as primary acting structure have a group of mechlorethamine 
(Figure 1.1A). This group has nucleophilic activities and attacks chemical 
groups with condensed negative charge such as –NH2 or -SH. The observed 
wide spectrum of activities of mustard analogs can be explained by their high 
potency to generate double strand adducts between N7-amino groups of 
guanidine. New substances such chlorambucil, bendamustin, melphalan, 
cyclophosphamide (Figure 1.1 B, C, D, E) were introduced in clinical practice.    
Mustard cytostatics are mainly used for the treatment of blood cancers. Short 













Figure 1.1 Structure of cytostatics based on the mustard group: A - 









Name  Treated disease Transporter type Side effects  






Not identified  nausea, vomiting, diarrhea, 
seizures, tremors, muscular 




Bendamustin multiple myeloma, ovarian 
cancer 
Not identified nausea, vomiting, diarrhea, 
seizures, tremors, muscular 
twitching, confusion, agitation, 
ataxia, 
Melphalan multiple myeloma, ovarian 
cancer, melanoma 
LAT1 [24], OCT3 nausea, vomiting, bone marrow 
suppression, hair loss, rash, 
itching 
Cyclophosfamide Lymphomas, leukemia, 
antirheumatic drugs 
Not identified bone marrow suppression, 
stomach ache, diarrhea 
Ifosfamide testicular cancer, breast 
cancer, lymphoma, lung 
cancer, cervical cancer, 
ovarian cancer, bone cancer 
MCT1 [25-27] bone marrow suppression, 
stomach ache, diarrhea 
 
Table 1.3 Characteristic of mustard based cytostatic 
 
1.3.1.2 Alkyl sulfonates 
 
This class of alkylating substances is the presented by busulfan (Figure1.2). 
The main biological activity is based on the production of cross-links in the 
DNA. Busulfan is used for the treatment of chronic myeloid leukemia (CML), 
chronic lymphocytic leukemia (CLL), and for inhibition of bone marrow before 



















































































The mechanism of action is a classical nucleophilic attack at electron-dense 
enriched groups such as –NH2, -SH. Cisplatin shows affinity to DNA and RNA. 
After reaction of DNA with cisplatin, N7-guanosine and cytosine adducts are 
obtained. After cisplatin treatment, DNA loses its biological functions. Platinum 
adducts can be removed by excising repair. This kind of reparir produces 
double stranded breaks and can include changes in nucleotide sequence. Many 
proliferative cells are very sensitive to DNA break. Treatment of such cells with 
cisplatin leads to apoptosis. Cisplatin is also used as pretreatment of radiation 
therapy of cancer diseases. The effect of X-ray radiation is amplified by cisplatin 
treatment. This effect is based on producing hyperoxide radicals by platinum 
ions when they meet an X-ray photon.  In clinical practice, other platinum 
analogs such carboplatin, nedaplatin, and oxaliplatin are widely used (Figure 
1.3 B, C, D). These substances produce fewer side effects in comparison to 
cisplatin. It was shown that cisplatin can be transported by OCT2 [11]. 
Carboplatin had a high affinity to OCT1 and OCT2 [54]. The usage of platinum 
compounds and their side effects are summarized in table 1.4.   
 Name  Treated disease Transporter type Side effects  
Cisplatin small cell lung cancer, and 
ovarian cancer, lymphomas 




Carboplatin ovarian carcinoma, lung, head, 
neck cancers 
OCT1, OCT2 [54] Nephrotoxicity, 
neurotoxicity, nausea, 
vomiting, ototoxicity,  
Nedaplatin ovarian carcinoma, lung, head, 
neck cancers, lymphomas 
Not identified nausea, vomiting, bone 
marrow suppression, hair 
loss, rash, nephrotoxicity, 
neurotoxicity 
Oxaliplatin colorectal cancer Not identified bone marrow suppression, 




Table 1.4 Characteristic of platinum based compounds 









































































































1.3.1.5.1 Folate analogs 
  
This group of compounds is including analogs of folic acid (Figure 1.5 A). 
Methotrexate is the most prominent member of the antifolate group and is used 
for treatment of leukemia in children. Methotrexate reversibly and competitively 
inhibits dehydrofolate reductase (DHFR) Fig. 1.5B [90]. The deficit of reduced 
folate leads to the inhibition of nucleoside and protein synthesis and cell, may 
undergo apoptosis. This mode of action is exhibited by all members of the 
antifolate group. In clinical practice are used pemetrexate and raltitrexed (Figure 
1.5 C, D). The usage of antifolate compounds and their side effects are 
summarized in table 1.5.   
A B 
D C 
Figure 1.5 Structural formulas of antifolate drugs: A - folic acid, B -methotrexate, 
C – 
pemetrexate, D - raltitrexed 





Methotrexate acute lymphoblastic 
leukemia, Crohn's disease, 
psoriasis, psoriatic arthritis 
[91] 
OAT1, 3, 4 [8] Anemia, neutropenia, 
bruising, nausea, 
hepatitis 
Pemetrexate pleural mesothelioma, non-
small cell lung cancer [92] 
Not identified Anemia, neutropenia, 
bruising, nausea, 
hepatitis 
Raltitrexed Different types of cancer, 
inhibitor thymidine 
synthetase [44] 




Table 1.5 Characteristic of antifolate compounds 
 
1.3.1.5.2 Antimetabolite nucleoside analogs 
 
Nucleoside cytostatics mainly block enzymes involved in nucleotide 
metabolism. There exist many antitumor active nucleoside substances. Most 
frequently used in clinical practice are fludarabine, mercaptopurine, 
capecitabine, fluorouracil, and gemcitabine (Figure 1.6 A, B, C, D, E). The 



















  Figure 1.6 Structural formulas of nucleoside cytostatics: A- fludarabine, B- 
mercaptopurine, C- capecitabine, D- fluorouracil, E- gemcitabine 
 
 
Name  Treated disease Transporter type Side effects  
Fludarabine Blood cancers [18] ENT1, 2  opportunistic infections, 
neutropenia 
Mercaptopurine non-Hodgkin's lymphoma, 
polycythemia vera, psoriatic 
arthritis [93] 
GLUT-1, ENT1 Anemia, neutropenia, 
myelosuppression 




Fluorouracil Colorectal cancer, pancreatic 
cancer 
ENT1, 2 myelosuppression, 
mucositis, dermatitis 
Gemcitabine Lung cancer, pancreatic 
cancer, bladder cancer  
ENT1, 2 Anemia, neutropenia, 
myelosuppression 
 
Table 1.6 Characterization of nucleoside cytostatics  
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1.3.1.6 Topoisomerase inhibitors 
 
This group of cytostatics was mainly isolated from plants as alkaloids. This 
group can be divided by their affinities into topoisomerase I inhibitors and 
topoisomerase II inhibitors. Topoisomerases play an important role in cell cycle. 
Topoisomerases are acting on secondary and tertiary structures in DNA. 
Topoisomerase I is present as a single protein molecule [94]. To release DNA 
concatamers, topoisomerase does not use ATP energy. A potent inhibitor of 
topoisomerase I is campotecin, a cytotoxic quinoline alkaloid isolated from 
Camptotheca acuminate [95]. Other campotecin analogs are irinotecan and 














Figure 1.7 Structural formulas of topoisomerase I inhibitors: A - campotecin, B -  
topotecan, C - irinotecan  
 
The second enzyme topoisomerase II, has two subunits and uses ATP as 
energy source for their action. It is a high fidelity enzyme included in the 
mammalian DNA polymerase complex. Inhibitors of topoisomerase II are based 
on podofillotoxin isolated from Podophyllum peltatum [96]. In clinical practice 
etoposide and teniposide are used (Figure 1.8). The usage of topoisomerase 
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Figure 1.8 Structural formulas topoisomerase II inhibitors: A - podofillotoxin,  




Name  Treated disease Transporter type Side effects  
Irinotecan colon cancer[97] Not identified  Diarrhea, neutropenia 
Topotecan ovarian cancer, lung cancer Not identified Diarrhea, anemia, 
susceptibility to 
infection 
Etoposide lung cancer, testicular cancer, 
lymphoma, non-lymphocytic 
leukemia, head and neck 
cancer [98] 
Not identified low blood pressure, 
hair loss, 
diarrhea 
Teniposide acute lymphocytic leukemia Not identified nausea, vomiting, 
diarrhea 
 
Table 1.7 Characterization of topoisomeraseI and II inhibitors 
 
1.3.1.7 Antracycline cytostatics 
 
Antracycline antibiotics are wide range activity cytostatics primarily isolated from 
Streptomyces peucetius [99]. The distinctive feature this group of drugs is the 
presence of an antracycle ring. The mechanism of action of antracyclins is not 
clear. A high potency to DNA intercalation and inhibition of RNA translation was 
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demonstrated. Doxorubicin was reported acting as inhibitor of topoisomerase 
II[100].  The structural formulas of most popular antracyclines are mentioned in 
figure 1.9. The usage of antracycline cytostatics and their side effects are 
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Figure 1.9 Structural formulas of antracyline cytostatics: A - doxorubicin,             
B - daunorubicin, C - mitoxantron 
 
 
Name  Treated disease Transporter type Side effects  
Doxorubicin leukemias, Hodgkin's 
lymphoma, bladder, breast, 
stomach, lung, ovaries, 
thyroid cancers, soft tissue 
sarcoma 
Not identified arrhythmias, 
neutropenia, bruising, 
nausea, alopecia  
Daunorubicin AML, neuroblastoma, 
chronic myeloid leukemia 
Not identified arrhythmias, 
neutropenia, bruising, 
nausea, alopecia 
Mitoxantron metastatic breast cancer, 
acute myeloid leukemia, and 
non-Hodgkin's lymphoma 
Not identified nausea, vomiting, hair 
loss, heart damage 
 






1.3.2 Cytostatics disturbing the mitotic spindle 
 
This group of cytostatic agents can be divided into two groups acting in an 
opposite way and obtained from different sources. The first group taxol derived 
substances docetaxel and paclitaxel (Figure 1.10). These substances acting on 
the microtubules and stabilizes their structure [101]. After treatment cell lose the 
ability to change microtubule structure and to divide. The second group of 
mitotic spindle acting cytostatics comprises vinca alkaloids. These substances 
also interact with cytoskeletal microfilaments, but their mode of action in the 
disruption of the microtubular net. Clinically used are vinblastine, vincristine 
(Figure 1.10) [101]. The use of taxenes, vinca derivatives and their side effects 
are summarized in table 1.9.  
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Figure 1.10 Structure formulas of anti-mitotic drugs: A - docetaxel,                     






Name  Treated disease Transporter type Side effects  
Docetaxel Breast, non small-cell lung 
cancer 
Not identified Neutropenia, anaemia, 
liver dysfunction 
Paclitaxel lung, ovarian, breast cancer, 
head and neck cancer, 
advanced forms of Kaposi's 
sarcoma 
Not identified Nausea, vomiting, skin 
rash, 
Vinblastine Hodgkin's lymphoma, non-
small cell lung cancer, breast 
cancer and testicular cancer 
Not identified peripheral neuropathy, 
hyponatremia, 
constipation and hair 
loss 
Vincristine non-Hodgkin's lymphoma, 




Not identified peripheral neuropathy, 
hyponatremia, 
constipation and hair 
loss 
 
Table 1.9 Characterization of anti-mitotic cytostatics  
 
1.3.3 Substances acting on the estrogen receptor 
  
This group includes substances which modulate the activities of the estrogen 
receptor. Estrogen receptors mediate expression of many oncogenes. 
Proliferations of 60% of breast cancers are driven by the estrogen receptor. 
Estrogen receptor positive breast cancer is treated with tamoxifen. Tamoxifen is 
acting as antagonist of the estrogen receptor. The active form of tamoxifen is 
produced after hydroxylation to 4-hydroxytamoxifen by CYP2D6 (Figure.1.11). 
In clinical practice, tamoxifen is widely used for correction of reproductive 
dysfunctions in men and women. As mentioned previously, breast cancer and 
prostate cancer are treated with tamoxifen. In 10-15% of the patients a total 
remission is observed after tamoxifen treatment [102]. In comparison to other 
cytostatics, tamoxifen therapy has weak side effects and has an increased risk 















Figure 1.11 Structural formulas of tamoxifen (A) and his active 




Active transport of drugs in cells is an important factor for the cytostatic action. 
The first aim of our work was to find which transporters demonstrate significant 
expression levels in malignant renal cells. The second aim was to characterize 
the activity of expressed transporters. The third aim was to find cytostatic 
substances which can be delivered to tumor cells with a help of specific 
transporters. The fourth aim was to investigate how sensitivity of tumor cells to 
certain cytostatic drug depends on their ability to deliver it inside with a help of 





2. Materials and methods 
2.1. Materials 
2.1.1. Primers 
Specific primers for RT-PCR study were obtained from MWG Biotech AG (Martinsried, 










hOAT1_933 for gggcaccttgattggctatgtc  
502 
 
58 hOAT1_1434 rev gatgacaaggaagcccacaagc 
SLC22A7 
(OAT2) 
hOAT2_835 for tctgcacgctggcttctgac  
552 
 
59,4 hOAT2_1386 rev tgtctgtctgagcaccgtaggg 
SLC22A8 
(OAT3) 
hOAT3_871 for cttcctatcatcctggtggac  
549 
 
53,6 hOAT3_1419 rev tagaggaagaggcagctgaag 
SLC22A12 
(OAT4) 
hOAT4_130 for catggcgttctcgaagctc  
593 
 












OCT1_115 for gtggatgacattctggagca  
485 
 
53,6 OCT1_599 rev ccgagagagccaaacaaga 
SLC22A2 
(OCT2) 
OCT2_2199 for accaagagtgaaccctaatgc  
606 
 
54,2 OCT2_2803 rev tagaccaggaatggcgtga 
SLC22A3 
(OCT3) 
OCT3_1293 for tgtcactgcgttcttaccag  
433 
 
54,3 OCT3_1725 rev tccttctttctgtctttgtcgg 
SCL22A16 
(OCT6) 
OCT6_1466 for ctgtggtgtcgttatggtgat  
224 
 
54,1 OCT6_1689 rev tccaaatgctgctgaggtc 
Table 2.1.  Characteristics of primer pairs which were used for PCR screening of 
the expression level of the SLC22A family transporters. 
Transporter 
family name 

































Table  2.2.   Characteristics of primers pairs which were used for PCR screening of 














CNT1_1146for tctttgtgagccagaccgag  
460 
 
55,3 CNT1_1605rev aggatgtaggagcagatgagc 
SLC28A2 
(CNT2) 
CNT2_1068for atgactggagggtttgccac  
443 
 
56,5 CNT2_1510rev accatctcagccaccattgg 
SLC28A3 
(CNT3) 
CNT3_171for gagaacgagaacacatcagg  
551 
 
52,6 CNT3_721rev tacattatgagcccaccgaa 
SLC29A1 
(ENT1) 
ENT1_1114for tgaggtcaagtccagcatcg  
462 
 
55,9 ENT1_1575rev caggcagtccttctgtccat 
SLC29A2 
(ENT2) 
ENT2_723for gctcctccagtctgatgaga  
513 
 
54,5 ENT2_1235rev accaggtagccattagaaacg 
SLC29A3 
(ENT3) 
ENT3_470for actggtgaaggtggacact  
513 
 
54,1 ENT3_987rev ggtagatgaggctggtgatga 
 
Table 2.3. Characteristics of primer pairs which were used for PCR screening of 






















MCT1_1183for gtatttctttgcggcttccgttg  
512 
 
57,6 MCT1_1694rev agactggactttcctcctccttg 
SLC16A7 
(MCT2) 
MCT2_334for ggttggattgtggttggagc  
564 
 
55,7 MCT2_897rev cttagaagtggtttgattgggtcc 
SLC16A3 
(MCT3) 
MCT4_864for accatcctgggcttcattgac  
450 
 
56,7 MCT4_1313rev tggctctttgggcttcttccta 
 
Table 2.5. Characteristics of primer pairs which were used for PCR screening of 













LAT1_1001for cgtggacttcgggaactatcac  
558 
 
57,2 LAT1_1558rev ttctgacacaggacggtcgt 
SLC7A8 
(LAT2) 
LAT2_976for agccctctgctatgctgaac  
454 
 
55,9 LAT2_1429rev ctgaaggaaagccagtgcga 
 
Table 2.4. Characteristics of primer pairs which were used for PCR screening of 














NADC3_1422for tgctgctcatcactgtggt  
619 
 
54,7 NADC3_2040rev gagagatacctgggctttgaac 
 
Table 2.6. Characteristics of primer pairs which were used for PCR screening of 














RFT_886for tctggtgggtcttcaactcg  
486 
 
55,6 RFT_1372rev aactggaactgcttgcgga 
SLC19A2 
(ThTr1) 
ThTr1_1241for ctgtgggtaacatttgggtgtg  
481 
 
55,1 ThTr1_1721rev tagtcaagtggctgctgtgaag 
 
Table 2.7. Characteristics of primer pairs which were used for PCR screening of 
















MRP1_4421 for20 aaggacttcgtgtcagccct  
476 
 
57,2 MRP1_4897 rev22 tttggtttcagtgtgggaggc 
ABCC2 
(MRP2) 
MRP2_3831 for19 acattgtggctgttgagcg  
504 
 
55,2 MRP2_4334 rev21 cctctgtcacttcgtgggata 
ABCC4 
(MRP4) 
MRP4_1812 for20 atgcggaagttagcagacac  
518 
 
53,6 MRP4_2329 rev21 ccagtatgaaagccaccaatc 
ABCB1 
(MDR1) 
MDR1_1854for cctgtattgtttgccaccacg  
595 
 
56,3 MDR1_2428rev atccacggacactcctacga 
 
Table 2.8. Characteristics of primer pairs which were used for PCR screening of 




Chemicals were bought from Sigma-Aldrich (Hamburg, Germany), Applichem 
(Darmstadt, Germany) Merck (Darmstadt, German) and Calbiochem 
(Gibbstown, USA). Radioactive chemicals were bought from Amersham 




Taq polymerase was purchased from Promega GmbH (Göttingen, Germany). 
Restriction endonuclease were purchased from New England Biolabs
® 
Inc 
(Beverly, MA, USA) or MBI Fermentas (Vilnius, Lithuania). T4 DNA ligase was 
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purchased from Boehringer Mannheim (Mannheim, Germany). Collagenase 
CLS II was purchased from Biochrom KG (Berlin, Germany). 
 
 





JM109 Promega GmbH endA1, recA1, gyrA96, thi, hsdR17 (rk–, mk+), relA1, supE44, 
Δ( lac-proAB),  (F´ traD36, proAB, laqIqZΔM15). 
TOP 10F’ Invitrogene F’{lacIqTn10(TetR)}, mcrA, Δ(mrr-hsdRMS-mcrBC), o80lac 
ZΔM15, ΔlacX74, recA1, araD139, Δ(ara-leu)7697,gal U, gal 
K, rps L (StrR) endA1, nupG 
 
Table 2.9 Bacterial strains used in this study 
 
2.1.5. Plasmid vector 
 
For TA cloning the pGEM®-T Easy vector from Promega GmbH (Göttingen, 
Germany) was used. It includes a multiple cloning site (polylinker), containing 
sites for different restriction endonucleases, and primer sequences (universal 
and reverse primers) necessary for DNA sequencing. The PCR products can be 
inserted in the linearized vector between part of LacZ gene, which has single, 
overlapping deoxythymidine (T) residues.  The pGEM®-T Easy vector map is 
presented in Figure 2.1. For cRNA preparation the pSPORT1 vector with 
hOCT3 cloned in 5’ SalI and 3’ NotI sites was used. The pSPORT1 vector map 


































2.1.6. Used kits  
 
Application  Kit Manufacturer 
Bacterial plasmid purification NucleoSpin Plasmid Kit Macherey-Nagel  
PCR product purification  NucleoSpin Extract Kit Macherey-Nagel 
TA cloning  pGEM®-T Easy Vector System 
II 
Promega corporation 
cRNA synthesis mMASSEGE 
mMACHINE® T7 
Ambion 
ATP amount measurement ATP Kit SL Biothema 
 
Table 2.10 Kits used in this work 
2.1.7 Software 
 
Program Usage Reference 
Chromas Sequence reading program Technesium Pty Ltd 
DNAMAN Primer design  Lynnon Ltd 
Microsoft Excel Evaluation of uptake and 
sensitivity experiments 
Microsoft Corporation  
Sigma Plot Graphic preparation   Jandel Corporation 
EndNote  Managing of bibliographic 
references 
Wintertree Software Inc. 
Vector NTI  DNA alignment, cloning  Invitrogene Corp. 
 





Online used software 
Program Usage Reference 




Blast  Sequence alignment  http://www.ncbi.nlm.n
ih.gov/blast/Blast.cgi 









Real-time PCR amplifcator  Abi Prism 7000 Applied Biosystems (Laguna 
Beach CA,USA) 
Centrifuges  Biofuge fresco  Heraeus (Osterode, 
Germany)  
Circulating water baths  D8  Haake (Karlsruhe, Germany)  
Dissection microscope  Stemi1000  Zeiss (Jena, Germany)  
Gel chamber  Midi  MWG-Biotech (Ebersberg, 
Germany)  
Gel documentation  Gel Print 2000 I  Biophotonics (Ann Arbor, MI, 
USA)  
Electroporator  Easyject  Equibio (Monchelsea, 
England)  




Nanoliter injector    World Precision Instruments 
(SarasotaFL, USA)  
pH meter  pH-Meter 611  Orion Research Inc (Beverly 
MA, USA)  
Power pack  P24  Biometra (Göttingen, 
Germany)  
  LKBBromma2297  Pharmacia (Uppsala, 
Sweden)  
Scintillation counter  1500 Tri-Carb  Packard Instrument Co 
(Meriden CT,USA) 
  2100 TR  Packard Instrument Co 
(Meriden CT,USA)  
Shaking incubator  3031  GFL (Burgwedel, Germany)  
Spectrophotometer  GeneQuant II  Pharmacia (Uppsala, 
Sweden)  
Speed vacuum concentrator  SVC 100E  Savant (Holbrook NY, USA)  
Thermocycler  PTC-200  MJ Research (Watertown MI, 
USA)  
UV transilluminator  TM40  UVP Inc (Upland, CA, USA)  
Vortexer  MS1  IKA (Staufen, Germany)  
Multi-plate reader  Mithras LB 940 Berthold (Wildbad, Germany) 
Microscope Wild M3C Leica Microsystems (Wetzlar, 
Germany) 
Electro measurement unit Model OC 725-C Warner instruments 
corporation, (Hamden, USA) 
Two channel paper plotter    model BD 112 Kipp & Zonnen(Delft, 
Netherlands) 
 







2.2. Methods  
2.1.1. Renal cancer cell  (RCC)  lines. 
  
A498 cell lines (Renal epithelial cell carcinoma cell line) 
ATCC Number   HTB-44 ™ 
Organism    Homo sapiens (Human female 52 years) 
Source    Kidney 
Disease    Carcinoma 
Growth properties   Adherent 
Morphology    Epithelial 
 
LN 78 (Clear renal cell carcinoma) 
Organism    Homo sapiens (Human female 73 years) 
Source    Kidney 
Disease    clear renal cell carcinoma 
Growth properties   Adherent 
Morphology    Epithelial 
 
786-O (renal cell adenocarcinoma cell line) 
ATCC Number   CRL-1932 
Organism Homo sapiens (Human Caucasian male 58 
years) 
Source    Kidney 
Disease    renal cell adenocarcinoma 
Growth properties   Adherent 
Morphology    Epithelial 
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ACHN (renal cell adenocarcinoma cell line) 
ATCC Number   CRL-16112 
Organism    Homo sapiens (Human caucasian male 22 
years) 
Source    Kidney 
Disease renal cell adenocarcinoma (derived from     
metastatic site: pleural effusion) 
Growth properties   Adherent 
Morphology    Epithelial 
RCCNG1  
Primary cell culture  
 
2.2.2. Cell culture 
 
For the expression studies of uptake transporters, 5 cell lines derived from 
kidney tumor tissue were used: A498, ACHN, LN78, RCCNG1 and 786-O. All 
cell lines were kindly provided by Dr. Hassan Dihazi and Prof. Dr. Gerhard A. 
Müller, Dept. of Nephrology, Uni-Klinikum, Göttingen. To investigate the 
interaction of anionic cytostatics with the organic anion transporters we used 
HEK-293 cells stably transfected with OAT1 or OAT3.    
The cells were cultivated in Quantum 263 (RPMI 1640 based medium 
supplemented with chelated iron and growth factors) or Trex (High glucose 
DMEM medium, 10% fetal bovine serum, 5 µg/ml blascitidine, 2 mM L-
glutamine) medium at 37°C, and 5% CO2. The media were supplemented with 
100 U/ml penicillin and 100 µg/ml streptomycin. For harvesting, the cells were 
washed with PBS (140 mM NaCl, 8 mM Na2HPO4, 1 mM KH2PO4, 1 mM KCl) 
and incubated 5 -10 min with Medium C (1 mM EGTA, 85 mM NaCl, 17,5 mM 
NaHCO3, 3,9 mM KCl, 0,8 mM KH2PO4 and 10 mM glucose). After the 
incubation the cells were intensively mixed with medium for detaching from the 
plastic dish. The cell suspension was transferred to 15 ml falcon tubes. After the 
centrifugation for 5 min at 1000 rpm the cells pellet was resuspended in medium 
and seeded in culture dish, 24 well plates or used for RNA extraction.  
  
2.2.3. RNA preparation 
 
 For the RNA preparation the cells were harvested at 90 -100% of confluence 
and the total-RNA extraction was carried out by an RNA isolation kit (Promega). 
The RNA isolation was performed according to the manufacturer’s protocol. 
Briefly, the pellet of 1×106 cells was resuspended in 175 µl of Lysis Buffer. The 
suspension was diluted with Dilution Buffer and heated for 3 min at 70° C and 
centrifuged for 10 min at 14,000 rpm. The supernatant was transferred to a new 
tube and after addition 200 µl of 95% ethanol the samples were mixed by 
intensive pipetting. To separate nucleic acids from solution the silica spin 
column was used. Nucleic acid bound to the spin column was washed once with 
Wash Buffer. After the washing, bound DNA contaminants were removed by 
treatment with a DNAse mix for 15 min at room temperature. The reaction was 
stopped by addition of 200 µl DNAse Stop Solution. Spin column was washed 
twice with Washing Solution, dried by centrifugation for 2 min at 14,000 rpm. 
Bound total RNA was eluted with 30 -100 µl of nuclease-free water. The amount 
and quality of total RNA was measured with spectrophotometer.  
 
2.2.4. cDNA synthesis 
 
Total RNA was used for the preparation of cDNA. For this purpose, Promega 
Reverse Transcription MuLV reverse polymerase RNAse H (-) point mutant was 
used. The reaction mix consisted of:  RT reaction buffer 5 x (100 mM Tris-HCl 





MuLV polymerase 200 U, random primer N6 2,5 µg/µl, total RNA  2 µg, and 
nuclease free water up to the volume of 20 µl. The reaction mixture was divided 
into two mix parts: the first containing total RNA, random primer, water, and the 
second mix with buffer, dNTP and MuLV polymerase. The first mix was heated 
to 70° for 5 min to denature the RNA, and then cooled down on ice for 2 min. 
Then, the second mix was added and the reaction was carried out for 60 min at 
37°C. After the incubation, the mixture was incubated for 10 min at 70°C in 
order to deactivate the MuLV polymerase. Prepared cDNA stock was diluted at 
a ratio of 1:3 with nuclease-free H2O and stored at -20°C. 
 
2.2.5. Polymerase chain reaction 
 
To evaluate the expression level of the uptake transporters, the polymerase 
chain reaction (PCR) was performed on the obtained cDNA samples. The PCR 
components were mixed as follows: Master Mix to 50 µl total volume:  10x 
Buffer (10 mM Tris-HCl (pH 9.0 at 25°C), 50 mM KCl and 0.1% Triton® X-100 ), 
200 µM dNTP of each, reverse and forward primer 20 pmol of each, nuclease 
free water till 50 µl. Then the tubes with reaction mixture were placed in a 
thermocycler, and the following PCR program was used: initial denaturation for 
3 min at 94°C, then 35 to 40 cycles at 94°C and 40 sec denaturation, 50 sec of 
annealing at the temperature specific for each pair of primers (Table 2), and 60 
sec at 72°C for elongation. The total PCR reaction was finished with 5 min of 
elongation at 72°C. To avoid nonspecific reactions, the annealing temperature 
was tested for each primer pair prior to the expression studies. For the testing, 





2.2.6. Agarose gel electrophoresis  
 
For the visualization of PCR fragments (300-600 bp), 1% agarose gels were 
used. Gels were prepared from solid agarose that was boiled in 1 x TBE (Tris 
0.89M, EDTA-Na2 20 mM, 0.89 M H3BO3) buffer. After the complete dilution, 
the solution was cooled down to 70° C and EtBr (ethidium bromide) was added 
to a final concentration of 0.5 µg/ml. The solution was then immediately poured 
into the mold. After the agarose polymerization (30 min) the samples were run 
for 1-1.5 h at 80-120V. The results were visualized and photo-documented by a 
Dual Intensity Ultraviolet Transilluminator.  Before the PCR of target gene the 
cDNA amounts used for reaction were equilibrated in accordance to the amount 
of signal obtained from the PCR analysis of the GAPDH, housekeeping gene in 
the corresponding sample.  
 
2.2.7. TA cloning  
 
The verification of PCR product was provided by sequencing. Before the 
sequencing procedure the PCR product was cloned into the pGEM T Easy 
vector with the use of the pGEM®-T Easy Vector System II kit. The desired 
PCR product was purified from the agarose gel with the use of DNA 
NucleoSpin® Extraction II kit (the piece of the agarose gel containing the 
relevant band was cut and then melted in NT buffer). Then the PCR product 
was bound to NucleoSpin® Extract II column and washed once with NT3 buffer. 
After that, the DNA was eluted from the column with Elution Buffer and the 
amount and quality of DNA were measured with  a spectrophotometer. 
 After cleaning of PCR fragment the ligase reaction was set up as follows: 
Ligase buffer 2x (60 mM Tris-HCl (pH 7.8 at 25°C), 20 mM MgCl2, 20 mM DTT 





nuclease free H2O to 10 µl of the end volume. The amount of the PCR product 
used for ligase reaction was calculated according to the formula:   
    
The ligation reaction was performed at 4° for 16 h. The products of the ligase 
reaction were further used for the transformation of the E.coli JM109 strain. For 
this purpose, the chemically competent JM109 E.coli cells were thawed on ice. 
Then, 1-2 µl of ligase reaction was added to the vial containing 50 µl of bacterial 
cell pellet and incubated for 30 min on ice. After the incubation the vial was 
transferred to water bath and heat shocked for 45 s at 42° C. For the heat 
shock, the vial was transferred on ice for 2 min and then the pellet was 
resuspended in 800 µl of pre-warmed LB medium and incubated for 1h at 37°C 
with vigorous shaking. During this process, only the transformed bacterial cells 
gained antibiotic resistance and were able to grow on Petri dishes with 1,5% 
agar containing 100 µg/ml ampicillin. Thus, the bacteria were spread on the 
agar plate and incubated for 16-24 h for white-blue screening.  
As the target gene insertion in the vector occurred in the β-galactosidase 
sequence, the bacteria containing the vector with insertion lost their capability to 
gain a blue color when growing on X-gal (5-Bromo-4-chloro-3-indolyl β-D-
galactopyranoside) and IPTG (isopropyl β-D-1-thiogalactopyranoside) 
containing medium. Thus, after incubation on ampicillin-X-gal-IPTG containing 
plate, only white ones were selected. Then, the colonies were transferred to LB 
medium with 100 ng/ml of ampicillin and incubated at 37°C with vigorous 
shaking over night. Small drops of bacterial biomass were used for the PCR-





2.2.8. Bacterial plasmid DNA preparation 
 
 For plasmid DNA preparation the NucleoSpin® Plasmid kit  based on the alkali 
lysis principle was used. Bacterial pellet was mixed with 250 µl of buffer A1 
containing RNAse A. After 5 min of incubation 250 µl of buffer A2 was added 
and the bacterial cells were lysed by gentle mixing. For precipitation of proteins 
and genomic DNA, 300 µl of buffer A3 was used with further centrifugation for 
10 min at 14,000 rpm. The supernatant was transferred to NucleoSpin® silica 
column and after the binding the plasmid DNA was washed once with 500 µl of 
AW buffer to avoid contamination with protein and once with 600 µl of A4 buffer. 
Then, the plasmid DNA was eluted with the use of Elution buffer and DNA 
amount and quality were measured with a spectrophotometer.  
 
2.2.9. Plasmid DNA restriction 
 
For restriction reaction the following reaction mixture was prepared: 5 µl 10× 
reaction buffer (type depend from desired restriction enzyme), 0.5 µl 100× BSA 
solution, 10 µg plasmid DNA, 5-25 U restriction enzyme. The reaction runs for 
3-4 h at 37°C. After 0.5-1 µl of reaction mixture was analyzed on an agarose 
gel. When the digestion was proven the reaction mixture was purified by 
NucleoSpin Extract Kit as described previously.   
 
2.2.10. cRNA synthesis 
 
For oocyte transport experiments, specific hOCT3 cRNA was synthesized. All 
specific reagents and enzymes were obtained from the Ambion mMASSEGE 
mMACHINE® T7 Kit. pSPORT1 plasmid DNA with cloned hOCT3 cDNA was 
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used for synthesis. Plasmid DNA before reaction was treated by BamHI 
endonuclease where digest site on 3’-end of hOCT3 cDNA insert  to produce a 
linear plasmid structure. The reaction mixture was prepared by Ambion 
mMASSEGE mMACHINE® T7 Kit reagent: 10 µl (2× NTP mix), (2 µl 10× 
reaction buffer contain T7 primer), 2 µl (10× enzyme mix contain T7 RNA 
polymerase), 1 µg plasmid DNA, nuclease free water till 20 µl end volume. The 
reaction mixture was incubated for 1,5-2 h at 37°C. After incubation plasmid 
DNA was degrade by 1 U TURBO DNAse for 15 min at 37°C. Before usage, the 
cRNA was purified. To the reaction mixture was added 15 µl of 5 M ammonium 
acetate, 115 µl nuclease free water and 150 µl 2-propanol. For sedimentation of 
the cRNA reaction, the mixture was centrifugated for 45 min at 13,000 rpm. The 
resul precipitate was washed twice with 70% ethanol and dried for 15 min at 
RT. Dried cRNA was dissolved in 15 µl nuclease-free water. Concentration and 
quality was measured with a spectrophotometer at λ=260nm and the amount 
was calculated by the formula  were 40 is the coefficient for RNA. 






2.2.11. DNA sequencing 
  
The sequencing of target DNA was performed by the dye terminator cycle 
sequencing method (Applied Biosystems) at the Department of the 
Biochemistry, Göttingen University. The sequencing PCR mixture was prepared 
as follows: Reaction setup: 6 x SeqMix, 5x Buffer, 10 pmol primer, 300 ng of 
plasmid DNA, HPLC grade H2O to 10 µl of end reaction volume. One of the 
system component sequence MIX included four types of ddNTP labeled with 
four different fluorescent dyes and unlabeled dNTPs. In each amplification cycle 
thermostable polymerase produced casual length ssDNA product with has at 
the 3’-prime end one of the fluorescently labeled ddNTP. After the reaction, 
newly synthesized DNA was transferred into a clean tube. For DNA 
63 
 
precipitation, 50 µl of 100% ethanol with 1 µl of 3 M Na acetate, 1 µl of 125 mM 
EDTA were added and incubated for 5 min. After the precipitation, DNA was 
sedimented by centrifugation for 20 min at 14,000 rpm. DNA pellet was washed 
once with 70% ethanol, dried on air for 10 min, resuspended in 30 µl of HPLC 
grade water and sent to the Biochemistry Department. The obtained sequences 
were analyzed by ClustalW  
http://bioweb.pasteur.fr/seqanal/interfaces/clustalw.html or Blast 
http://www.ncbi.nlm.nih.gov/BLAST/ online software. 
 
2.2.12. Real-time PCR  
 
For the quantification of the target gene expression levels we used the real-time 
PCR. Two approaches in real-time PCR were used: SYBR Green I and TaqMan 
based methods as described before [103]. For the TaqMan based PCR the 
reaction mix included 2 x reaction buffer, 20x TaqMan probe, 5 µl of cDNA, 
nuclease free H2O till the volume of 25 µl. The thermocycler was programmed 
as follows: 2 min at 52°, 10 min at 95° and 40 cycles, including 15 s at 95° and 
1 min at 61°C. The SYBR Green I reaction setup included: reaction buffer 2x, 
forward primer and reverse primer 10 mM of each, cDNA  5 µl from RT-mixture,  
nuclease free H2O till 25 µl. The thermocycler was programmed as previously 
described for TaqMan.  
In order to evaluate the expression levels of the target gene, two approaches 
were used, which were appropriate for SYBR Green and TaqMan based PCR. 
To evaluate the results of SYBR Green based real-time PCR we used the same 
target DNA sequence, obtained via TA-cloning, which was added to the 
reaction mix in a known copy number. The expression level was then estimated 
by the comparison of signals from the cloned DNA with the signals from the 
studied samples, in a way previously described [104]. Additionally, for the 
verification of the SYBR Green based real-time PCR results we analyzed the 
64 
 
melting curves of an obtained product. For the analysis of TaqMan based real-
time PCR data ∆Ct evaluation method was used as described before [105].  
 
2.2.13. Radioactive transport studies in CHO cell stably transfected with 
hOCT3 
 
The cells were cultured in 24 well plates and grown until they reached 90 -100% 
of confluence. After that, the cells were washed three times with Mammalian 
Ringer solution (130 mM NaCl, 4 mM KCl, 1 mM CaCl2, 1 mM MgSO4, 20 mM 
HEPES, 1 mM NaH2PO4, 18 mM Glucose). The radioactive substrates were 
diluted for desired final concentration (e.g. 1 µM [H3]MPP) in Mammalian Ringer 
Solution, transferred to each well and incubated for 15 min. After the incubation, 
the plate was washed with ice cold PBS solution and the cells were lysed by 
addition of 500 µl 1N NaOH for 20 min. After the lysis the solution was 
neutralized with 1N HCl and transferred to scintillator vial. Upon the addition of 
2,5 ml of Lumasafe scintillation solution the results were obtained after 5 min of 
radioactivity counting in a scintillation counter (TriCarb 1500 Packard).  
 
2.2.14. [3H]thymidine incorporation assay 
 
The cells were incubated for 1 h with cytostatic drugs at different 
concentrations. After the incubation the cells were washed twice with medium. 
The radioactive thymidine was diluted with the medium to the final activity of 
0.2-1 µCi/ml. After 30 min incubation at 37°C, the cells were fixed with 5% 
trichloroacetic acid for 30 min at 4°C. The plate was then washed twice with 500 
µl of ice cold PBS and once with 500 µl of ice cold 95% ethanol.  For the full 
solubilisation of genomic DNA, the plate was incubated with 500 µl of 1N NaOH 
overnight. After the incubation, the solution was neutralized with 500 µl of 1N 
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HCl and then transferred to scintillator vials together with 2.5 ml of Lumasafe 
scintillation fluid. The results of the experiment were obtained after 5 min of the 
counting of incorporated radioactivity in the scintillation counter (TriCarb 1500 
Packard).  
 
2.2.15. BrdU incorporation method (ELISA) 
 
The amount of 10000 cells was seeded into 96 well plates and grown until 
reaching 50-70% confluence. The cells were then incubated for 1 h with the 
desired cytostatics and washed 2 times with the medium. After that, BrdU 
(Bromo-deoxyuridine) in the final concentration of 10 µM was added and 
incubated for 1 h. The cells were fixed with 70% ethanol for 30 min and washed 
3 times with PBS. To denature double-stranded DNA, cells were incubated for 
30 min with the solution containing 4N HCl and 0,5% Triton X-100. After 
incubation, the solution was washed out and the DNA mixture was neutralized 
with 0.1N Na3BO3 solution for 5 min and washed with PBS 3 times. For 
blocking of non-specific binding sites, the plate was incubated with 5% non fat 
milk, 0.1% Tween 20 for 3 h. After the blocking step, the plate was incubated 
with anti-BrdU antibody coupled with horse raddish peroxidase (Abcam) diluted 
1:500 in blocking solution for 3 h.  At the end, non-bound antibodies were 
removed by washing 3 times with 0.1% Tween 20.  
Evaluation of BrdU incorporation was provided by the visualization of 
peroxidase reaction with the use of specific substrate TMB (3,3′,5,5′-
Tetramethylbenzidine) in the solution including: 50 mM phosphate-citrate buffer,  
0.1mg/ml of TMB, 0.006% H2O2). The plates were incubated with TMB-solution 
from 10 to 20 min, until a deep blue color was obtained. Then the reaction was 
stopped with 0.1 M H2SO4 and the measurements were performed on λ=570 
nm using Multi-plate reader Mithras LB 940 (Berthold).   
2.2.16. MTT assay 
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Figure 2.3 Reduction of MTT to formazane blue 
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2.2.17. Comet assay 
 
For investigation of cytotoxic activity of topoisomerase I inhibitors, the alkaline 
single cell gel electrophoresis (Comet assay) was used. 2×105 cells were 
transferred onto 24 well plates and grown till 80-90% confluence. After 
cytostatic treatment, 1×104 cells were mixed with 85 µl 0.5% low-melting 
agarose and transferred on cover slips covered by 300 µl 0,6% normal melted 
agarose. Cover slips were cooled down in ice bath for 30 min. For release of 
DNA from cells, cover slips with agarose slices were incubated in lysis buffer  
(10 mM tris-HCl pH 10, 2,5 M NaCl, 100 mM EDTA, 1% Triton X-100, 10% 
DMSO) 1 h at 4°C. After lysis, cover slips were transferred into an 
electrophoresis chamber and covered by electrophoresis buffer (300 mM 
NaOH, 1 mM EDTA pH 13). Electrophoresis was performed at 25V, 300 mA 
(0,66 V/cm), for 30 min. To neutralize agarose, slices were washed 3× in 
neutralization buffer (Tris-HCl 400 mM pH7.4). Released DNA was stained by 
60 µl  EtBr solution for 10 min. Cover slips were examined on fluorescent 
microscope 400× with excitation filter at λ=510-590.  
 
2.2.18. Intracellular ATP concentration measurement 
 
ATP level was measured using the ATP Kit SL with modification. Cells were 
grown in 96 well plates till 50-60% confluence. After treating with cytostatics and 
incubating in normal medium for 24-48 h, the ATP level was measured. Cells 
were lysed in lysis buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA 
pH 8.0, 0.5% Triton X-100) for 15 min at RT. Therefore, cell extracts were 
diluted 1:20 with lysis buffer. 5 µl of sample was transferred into the reaction 
mix (160 µl Tris-EDTA buffer, 40 µl SL-reagent). Luminescence was 
measurement using the Multi-plate reader Mithras LB 940 (Berthold). To 
reaction mix containing sample 10µl diluted ATP standard was added, and 
luminescence measuring was repeated. The amount of ATP was calculated 
using the formula    where   is the sample 
luminescence,   is the sample luminescence after adding the ATP 
standard,  10  concentration of ATP standard (mol/l).  
 
2.2.19. Expression of hOCT3 in Xenopus laevis oocytes 
 
Xenopus laevis oocytes were used as expressing system for hOCT3 protein. 
Oocytes were injected with cRNA from the full clone of hOCT3. After 3 days of 
expression, oocytes were used for [3H]MPP uptake and electrophysiological 
investigation.  
 
2.2.20. Preparation of Xenopus laevis oocytes 
 
Individual stage V-VI oocytes were defolliculated by collagenase treatment. This 
procedure involved an overnight incubation of several ovarian lobes in 20 ml 
Barth’s solution (88 mM NaCl, 1 mM KCl, 0.3 mM Ca(NO3)2, 0.41 mM CaCl2, 
0.82 mM MgSO4, 15 mM HEPES, 12 µg/ml gentamycin, pH set to 7.4) 
containing 0.5 mg/ml collagenase (Type CLSII, Biochrom KG) at 18°C. On the 
following day, oocytes were washed several times with oocyte Ringer’s solution 
(ORI) (90 mM NaCl, 3 mM KCl, 2 mM CaCl2, 1mM MgCl2, 5 mM HEPES, pH 
was set to 7.4 ), incubated for 10 min in Ca
2+ 
free medium and then washed 
again 2-3 times with ORI solution. Oocytes were sorted and the “healthy” 






2.2.21. Oocyte injection 
 
cRNA was injected into the oocyte using a nanoliter microinjector with glass 
capillaries (Word Precision Instruments). In each oocyte 5-20 ng of cRNA in 22-
50 nl volume was injected. As negative control, oocytes injected by water were 
used. For injection oocytes were mechanically fixed in a microrow on a plastic 
chamber filled with ORI solution. After cRNA injection oocytes were transferred 
into 24 well cell culture plates with Barth’s solution. For expression injected 
oocytes were incubated 3 days at 18°C. Barth’s solution was changed every 24 
h and damaged oocytes were separated from healthy ones.   
  
   2.2.22. Oocyte uptake experiments 
 
Surviving oocytes were divided into groups containing 8-11 oocytes. Groups 
were transferred into 24 well plates which contained ORI uptake medium. For 
preparing of ORI uptake medium, [3H]MPP 0.25 µCi/ml (4-methyl-pyridinium 
acetate 80 Ci/mmol) was used. For inhibition studies inhibitors were dissolved in 
uptake ORI solution. Oocytes were incubated for 30-60 min at RT and 
transferred to ice-cold ORI solution to stop uptake process. To eliminate 
contamination from uptake solution, oocytes were washed 3 times. Then single 
oocytes were isolated from groups and transferred individually to the scintillation 
vial. To dissolve oocytes, 250 µl of 1N NaOH was added to the scintillation vial. 
After 2h incubation with shaking, alkali solution was neutralized by 250 µl 1N 
HCl. Upon the addition 2.5 ml of Lumasafe scintillation solution radioactivity was 
counted in the scintillation counter (TriCarb 1500 Packard).  
 
2.2.23. Two-electrode-voltage-clamp measurement in Xenopus laevis 
oocytes 
 
This method is based on the measurement of transport-mediated current at 
















Figure 2.4 Principle scheme for current measuring. 
 
After 3 days expression, oocytes were washed in ORI solution. Each oocyte 
was transferred into a plastic perfusion chamber. Before manipulation, glass 
electrodes (Borosilicate glass, Hihgenberg) were filled with 3M KCl solution. 
The chamber was connected to ground. In first control electrode was impaled 





in chamber and the current-donor electrode was introduced.  Then, the oocyte 
was fixed and perfusion was started (4ml/min). Intracellular voltage was 
observed at the central control unit (Model OC 725-C, Warner instruments 
corporation, Hamden, USA). The usual voltage level for healthy oocyte was 
observed at -29 to -37mV. For stabilization, the oocyte was perfused for 10-20 
min and the voltage level was controlled. In a stable oocyte, voltage did not 
change more than 2-3 mV. Therefore, the oocyte voltage level was clamped to -
60 mV. Perfusion was prolonged for additional 10 min to observe the oocyte’s 
current stability. For experimental procedure, different test substances were 
dissolved in ORI solution. Measurement was performed by perfusion of the 
clamped oocyte by different concentrations of test substances. Current changes 















 3. Results 
 
3.1 RT-PCR analysis of transporter expression in kidney cancer-
derived cell lines and tissue samples 
 
To explore the expression level of the uptake transporters in the tumor cells we 
performed a semi-quantitative RT-PCR for selected transporter proteins. The 
sequence data were obtained from the NCBI database (www.ncbi.nih.gov) and 
the primers were designed with the use of NCBI online software. The cell lines 
were obtained from the Dept. of Nephrology, and the kidney tumor as well as 
the normal kidney tissues from the same patient was kindly provided by the 
Dept. Pathology of the Universität klinikum, Göttingen, respectively. 
The results of PCR screening are shown in the following tables. They are 
presented as semi-quantitive estimation from the agarose gel. We evaluated 
our data by Gel Pro Analyser. Gels were saved as picture file in .jpg format. The 
program counted white pixels in marked bands.  Expression of single genes 
was divided by expression of GAPDH in the same sample. After evaluation of 
gene expression, ratio numbers were estimated. If the ratio of gene/GAPDH 
was <2, expression was counted as +, <3 = ++,<4= +++, <5 = ++++ (Figure 3.1, 
Table 3.1). The results were additionally proven by sequencing of each PCR 








































Figure 1.1 Representative gel for gene expression evaluation 
 
      Cell line 
 
Transporter 
A498 786-O RCCNG1 ACHN LN78 
Ratio 
Gene/GAPDH 
OAT1 0,57 0,99 0,23 1,13 1,03 
OCT3 5,42 4,01 0 0 1,16 
Evaluation OAT1   + + + + + 
OCT3 ++++ +++ - - + 
        
       Table 3.1 Example of gene expression evaluation  











The first transporter family screened with RT-PCR included organic anion 
transporters SLC22A6 (OAT1), SLC22A7 (OAT2), SLC22A8 (OAT3) and 
SLC22A11 (OAT4). Our data showed considerable variations in the mRNA 
levels for OATs in tumor tissue U675599T compared with normal tissue 
U675599N. In cell lines (786-O, A498, LN78) a medium expression level of 
OAT1 was observed. The cell lines RCCNG1 and ACHN had low expression 
levels in comparison to normal tissue. The OAT2 was detected at a low level 
only in the 786-O cell line. The expression of OAT2, OAT3 and OAT4 was 




The SLC22 organic cation transporter transporters OCT2 and OCT3 were 
highly expressed in the normal kidney tissue.  In the tumor tissue and kidney 
tumor-derived cell lines 786-O and A498 SLC22A3 (OCT3) was expressed at a 
level similar to or higher than that in normal tissue. In RCCNG1, LN78 and 
ACHN cells, no or a low expression of OCT3 was found. Except normal kidney 
tissue and the ACHN cell line, the expression of SLC22A1 (OCT1) was not 
detectable with RT-PCR. The expression of SLC22A2 (OCT2) was absent in all 
tumor cell lines. A low expression of SLC22A16 (OCT6) was observed in A498, 
ACHN, tumor tissue, and normal tissue.  
 
 
The organic cation/anion/zwitterion family SLC22 
       Cell     
Trans 
porters 
786-O RCCNG1 A498 LN78  ACHN U675599T U675599N 
OAT1 + + + + + + +++ 
OAT2 + - - - - - +++ 
OAT3 - - - - - + +++ 
OAT4 - - - - - + + 
OCT1 - - - - + - + 
OCT2 - - - - - +++ +++ 
OCT3 ++++ - ++++ + - +++ +++ 
OCT6 - - + - + + + 
 
Table 3.2. The results of RT-PCR screening of kidney tumor cell and tissue 
samples for the SLC22A family. The normal tissue is marked by yellow color, 
and malignantly transformed tissue by blue (- no amplification, + low 
amplification, ++ medium amplification, +++ high amplification, ++++ very 







3.1.2 The expression of organic anion-transporting polypeptide 
transporters (OATP) 
 
SLC21/SLCO21 proteins were shown to be functionally close to SLC22A 
transporter family. The RT-PCR data presented in Table 3.3 demonstrate an 
expression of all five types of OATPs in the cell lines 786-O and A498. The cell 
lines RCCNG1, ACHN, and tumor and normal kidney tissue did not express 
OATP-C.  The OATP-A, OATP-B and OATP-E had different levels of 
expression in these cell lines.  From the SLC21/SLCO family only OATP-B and 
OATP-E were expressed at high level in A498 and LN78 cells respectively. The 
other transporters of SLC21/SLCO family were present in the cell lines as well, 
but at lower levels in comparison with OATP-B and OATP-E. 
The organic anion transporter family SLC21/SLCO 
        Cell     
Trans 
porters 
786-O RCCNG1 A498 LN78  ACHN U675599T U675599N 
OATP-A + + + ++ + +++ + 
OATP-B ++ + ++++ - + +++ +++ 
OATP-C + - + - - - - 
OATP-E + + + +++ + + + 
 
Table 3.3.  The results of RT-PCR screening of kidney tumor cell and 
tissue samples for the SLC22A family. The normal tissue is marked by 
yellow color, and malignantly transformed tissue by blue (- no 
amplification, + low amplification, ++ medium amplification, +++ high 














3.1.3 The expression of sodium-coupled nucleoside transporters and 
equilibrative nucleoside transporters (CNT and ENT) 
 
The nucleoside transporters are presented by two families, namely SLC 28 
(sodium coupled nucleoside transporters, CNT) and SLC29 (equilibrative 
nucleoside transporters, ENT). The data obtained from RT-PCR analysis 
indicated that most of SLC28 transporters were not present in the selected cell 
lines. However, the A498 cell line showed a low expression of SLC28A1 (CNT1) 
(Table 3.4). In contrast to SLC28, the SLC29 family demonstrated high 
expression levels. A very high expression of SLC29A1 (ENT1) was found in all 
five kidney cancer cell lines. The SLC29A2 (ENT2) was expressed in almost all 
cell lines at different levels. The A498 did not show any expression of this 
transporter. The SLC29A3 (ENT3) appeared in all cell lines at a low level (Table 
3.5). 
The sodium-coupled nucleoside transporter family SLC28 
    Cell     
Trans 
porters 
786-O RCCNG1 A498 LN78  ACHN U675599T U675599N 
CNT1 - - + - - ++ ++ 
CNT2 - - - - - - - 
CNT3 - - - - - + - 
 
Table 3.4. The results of RT-PCR screening of kidney tumor cell and 
tissue samples for the SLC28 family. The normal tissue is marked by 
yellow color, and malignantly transformed tissue by blue (- no 
amplification, + low amplification, ++ medium amplification, +++ high 





The nucleoside transporter family SLC29 
       Cell     
Trans 
porters 
786-O RCCNG1 A498 LN78  ACHN U675599T U675599N 
ENT1 ++++ ++++ + ++++ ++++ ++++ ++++ 
ENT2 ++ ++ + ++++ +++ + + 
ENT3 + + + + + + + 
 
Table 3.5. The results of RT-PCR screening of kidney tumor cell and 
tissue samples for the SLC29 family. The normal tissue is marked by 
yellow color, and malignantly transformed tissue by blue (- no 
amplification, + low amplification, ++ medium amplification, +++ high 
amplification, ++++ very high amplification) 
 
3.1.4 The expression of L-amino acid transporters (LAT) 
 
The transporters LAT1 and LAT2, demonstrated a high or very high expression 
level in cancer cells and normal tissues. In general, SLC7A8 (LAT2) appeared 









The cationic amino acid and glycoprotein-associated amino acid 
transporter family SLC7 
       Cell    
Trans 
porters 
786-O RCCNG1 A498 LN78  ACHN U675599T U675599N 
LAT1 +++ +++ +++ +++ +++ +++ +++ 
LAT2 + + + - + ++++ ++++ 
 
Table 3.6. The results of RT-PCR screening of kidney tumor cell and 
tissue samples for the SLC7 family. The normal tissue is marked by 
yellow color, and malignantly transformed tissue by blue (- no 
amplification, +  low amplification, ++ medium amplification, +++ high 
amplification, ++++ very high amplification) 
 
3.1.5 The expression of monocarboxylate transporters (MCT)  
 
The monocarboxylate transporters showed high expression levels in kidney 
cancer cells (Table 3.7). Among the members of the MCT family the highest 
expression was observed for SLC16A1 (MCT1), while SLC16A2 (MCT2), and 
SLC16A4 (MCT4) demonstrated less expression. In addition, the expression of 









The monocarboxylate transporter family SLC16 
       Cell    
Trans 
porters 
786-O RCCNG1 A498 LN78  ACHN U675599T U675599N 
MCT1 ++++ ++++ ++++ ++++ ++++ ++++ ++++ 
MCT2 +++ +++ +++ +++ +++ +++ +++ 
MTC4 - +++ +++ +++ +++ +++ +++ 
 
Table 3.7.The results of RT-PCR screening of kidney tumor cell and 
tissue samples for the SLC16 family expression. The normal tissue is 
marked by yellow color, and malignantly transformed tissue by blue (- 
no amplification, + low amplification, ++ medium amplification, +++ 
high amplification, ++++ very high 
  
3.1.6. The expression of sodium dicarboxylate transporters 
(NaDC/SLC13) 
 
In Table 3.8 the expression levels of SLC13A3 is shown. Most of cell lines and 
normal tissue demonstrated the same expression level of SLC13A3 (NaDC 3). 









The human Na+-sulfate/carboxylate cotransporter family SLC13A3 
       Cell     
Trans 
porters 
786-O RCCNG1 A498 LN78  ACHN U675599T U675599N 
NaDC3 +++ +++ +++ + +++ +++ ++++ 
 
Table 3.8. The results of RT-PCR screening of kidney tumor cell and 
tissue samples for the SLC 13 family. The normal tissue is marked by 
yellow color, and malignantly transformed tissue by blue (- no 
amplification, + very low amplification, ++ medium amplification, +++ 
high amplification, ++++ very high amplification)  
 
3.1.7 The expression of reduced folate and thiamine transporters 
  
The SLC19 folate and thiamine transporter expression levels were studied in 
the cancer cell lines (Table 3.9). The thiamine transporter ThTr had the same 
level of expression as in normal tissues in all type of tested cell lines. The 
reduced folate transporter (RFT) expression level was higher in 786-O, LN78, 







The folate/thiamine transporter family SLC19 
       Cell     
Trans 
porters 
786-O RCCNG1 A498 LN78  ACHN U675599T U675599N 
ThTr +++ +++ +++ +++ +++ +++ +++ 
RFT ++ + + ++ ++ +++ +++ 
 
Table 3.9. The results of RT-PCR screening of kidney tumor cell and 
tissue samples for the SLC 19 family. The normal tissue is marked by 
yellow color, and malignantly transformed tissue by blue (- no 
amplification, + low amplification, ++ medium amplification, +++ high 
amplification, ++++ very high amplification) 
 
3.1.8 The expression of the ATP-binding cassette (ABC) transporter 
family  
 
All investigated members of ABC family (MRP1, MRP2, MRP4, and MDR1) 
were shown to be present in kidney malignantly transformed tissue at the same 
relatively high or very high level as in normal tissue (Table 3.10). Different 
expression levels were observed in the MDR1 transporter. The 786-O and A498 
cell lines had a very high expression level even comparison to tissue samples 
and the cell lines ACHN and LN78 showed low expression. The RCCNG1 did 








The human ATP-Binding Cassette (ABC) Transporter Superfamily 
       Cell     
Trans 
porters 
786-O RCCNG1 A498 LN78  ACHN U675599T U675599N 
MRP1 +++ +++ +++ +++ +++ +++ +++ 
MRP2 ++++ ++++ ++++ ++++ ++++ +++ +++ 
MRP4 ++++ ++++ ++++ ++++ ++++ ++++ ++++ 
MDR1 ++++ - ++++ + ++ +++ +++ 
 
Table 3.10. The results of RT-PCR screening of kidney tumor cell and 
tissue samples for the SLC 19 family. The normal tissue is marked by 
yellow color, and malignantly transformed tissue by blue (- no 
amplification, + low amplification, ++ medium amplification, +++ high 
amplification, ++++ very high amplification)   
 
 3.2 Quantification of the transporter expression levels in kidney 
tumor cells by real time PCR 
 
3.2.1 The expression of the organic anion transporter 1 (OAT1) 
 
  After screening the expression level of the SLC transporter family in several 
kidney tumor cells by semi-quantitative RT-PCR, we performed real-time PCR 
experiments to evaluate and quantify the expression of the organic anion 
transporter 1 (OAT1). The real-time PCR experiments were performed using the 
SYBR Green I method.  Figure 3.2 illustrates the results of the real-time PCR 
analysis of OAT1 expression level in kidney tumor cell lines and in tumor and 
normal tissue. The OAT1 expression level in normal tissue is 14 times higher 
than in tumor tissue and 44-50 times higher than in cancer cell lines. Among all 
analyzed samples, the highest level of the expression (around 2500 copies) 
was detected in A498 and a newly added cell line, SKRC17 cells. The second 
place according to OAT1 expression levels is taken by LN78 and 786-O cells 
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 c
igure 3.2. The expression level of OAT1mRNA in kidney cancer cells and 
tumor and normal tissues. The hOAT1 expression was equilibrated by 
omparison with hGAPDH and hHPRT. Means ± SEM were calculated 
from three independent experiments with three repeats each. 
 




Figure 3.2 demonstrates the data on OAT3 expression in cancer cell lines, 
normal and tumor tissues.  In normal tissue the levels of OAT3 expression was 
3000 times higher than in malignantly transformed tissue, and 12000 times 
higher than in cancer cell lines. The expression levels in tumor cell lines were at 
the lower border of detection. Thus, the highest level of expression detected in 
cancer cell lines was around 600 copies per sample in SKRC17cells. The LN78 
and RCCNG1 (not shown in Figure 3.3) cells had even lower expression levels, 
around 300 copies per sample. The cell lines 786-O and A498 contained 
approximately 200 copies per sample, while in ACHN the OAT3 expression was 
not detected. 
 



























Figure 3.3. The expression level of mRNA OAT3 in kidney cancer cells and 
tumor and normal tissue. The hOAT3 expression was equilibrated by 
comparison with hGAPDH and hHPRT. Means ± SEM was calculated from 








The comparison of obtained data for OAT1 and OAT3 expression is illustrated 
in figure 3.4. In normal tissue the expression of OAT3 was 10 times higher than 
that of OAT1. At the same time, in tumor tissue and cancer cell lines the 
expression levels of OAT1were 5-6 times higher than that of OAT3. 
 































Figure 3.4 Comparison of expression levels of OAT1 and OAT3 mRNA in kidney 
cancer cells and tumor and normal tissue. The hOAT1 and hOAT1 expression 
was equilibrated by comparison with hGAPDH and hHPRT. Means ±SEM was 
calculated from three independent experiments with three repeats each. 
 
3.2.3 The expression of organic cation transporter 3 
 
To more deeply study the expression of hOCT3 (SLC22A3) in RCC lines we 
chose five renal carcinoma cell lines, namely A498, ACHN, 786-O, RCCNG1 
and LN78. Upon the RNA isolation and reverse transcription, hOCT3 
expression was evaluated by TaqMan real-time PCR. The results of the real-
time PCR are summarized in Figure 3.5. We demonstrate that A498 and 786-O 
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RCC lines have the highest hOCT3 expression levels (12.5 and 6 cycles 
difference compared to ACHN and RCCNG1 cells). Medium expression levels 
of hOCT3 were observed in LN78 (4-5 cycles differences with ACHN and 
RCCNG1 cells). Therefore, for the next experiments we selected A498 as highly 







































A498 ACHN 7860 RCCNG1 LN78
Fig. 3.5 TaqMan real-time PCR hOCT3 examination of total RNA extracted 
from renal carcinoma cell lines. The hOCT3 expression was equilibrated by 
comparison with hGAPDH and hHPRT. Data means difference between lowest 
expression member (ACHN) and other tested RCC lines. Means ±SEM was 
calculated from three independent experiments with three repeats each. 
 
3.2.4 The expression of equilibrative nucleoside transporters 1,2 and 3 
 
The RT-PCR analysis demonstrated the expression of equilibrative nucleoside 
transporters in all RCC lines. To compare the ENT expression levels in more 
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detail the real-time TaqMan was applied. In the result it was demonstrated that 
in all RCC lines ENT3 had low expression, while ENT1 and 2 were expressed at 
different levels with an exception of A498 cells, where all the ENTs were poorly 
presented. ENT1 expression was 16.51 and 15.71 cycles higher in LN78 and 
ACHN cells respectively compared to A498 cells. In RCCNG1 and 786-O ENT1 
expression was detected respectively 14.53 and 10.73 cycles earlier in 
comparison with A498 cells. For the expression of ENT2 these numbers were 
relatively moderate and comprise 10.11 cycles, 11.65 cycles, 10.5 cycles and 
5.95 cycles more for ACHN, LN78, RCCNG1 and 786-O cells respectively.  
 










































Fig. 3.6 TaqMan real-time PCR hENT1,2,3 examination of total RNA extracted 
from renal carcinoma cell lines. The hENT1,2,3 expressions were equilibrated by 
comparison with hGAPDH and hHPRT. Data means difference between lowest 
expression member (A498) and other tested RCC lines. Means ± SEM were 






3.3 [3H]MPP uptake investigation in CHO-hOCT3 and RCC lines 
 
3.3.1 Inhibition of [3H]MPP uptake by cationic substances  
 
MPP is known as a substance specifically transported by OCTs. As ACHN and 
A498 cell lines did not show any expression of other OCTs (unpublished data), 
MPP uptake is mainly mediated by hOCT3. Thus, to investigate the activity of 
hOCT3, A498 and ACHN cells were tested for [3H]MPP uptake. The results 
were compared with hOCT3-stably transfected CHO and control CHO cells. The 
data are presented in Figure 3.7. The uptake of [3H]MPP in CHO-hOCT3 was 
3.5 ± 0.01 pmol/5 min, which was 11 fold higher compared to CHO cells (0.2 ± 
0.01 pmol/5 min, P<0.00001). hOCT3 mediated [3H]MPP uptake was 
significantly inhibited by 100 µM quinine (0.55 ± 0.02 pmol/5 min, P<0.00001) 
and 500 µM  unlabeled MPP (0.47 ± 0.05 pmol/5 min, P<0.00001). 
Tetraethylammonium (TEA) at a concentration of 1 mM inhibited [3H]MPP 
uptake only partially (1.32 ± 0.04 pmol/5min, P<0.00001). Non-transfected CHO 
cells did not show significant [3H]MPP uptake. In A498 cells the uptake of 
[3H]MPP was 10 fold higher compared to ACHN cells. The [3H]MPP uptake in 
A498 cells was also inhibited by 100 µM quinine (0.3 ± 0.003 pmol/5min 
P<0.00001) and 500 µM unlabeled MPP (0.31 ± 0.01 pmol/5min P<0.00001). 
Inhibition by 1 mM TEA caused 2 fold decreases in [3H]MPP uptake compared 
















































Fig. 3.7  Inhibition by known hOCT3 inhibitor of [3H]MPP uptake into CHO-
hOCT3. [3H]MPP uptake into stably transfected hOCT3-CHO cells and CHO. ■ 
hOCT3 expressing cells, □ mock cells. Data are means ± SEM of three 
independent experiments with four repeats each. *** P<0.0001 
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Fig. 3.8 Inhibition by known hOCT3 inhibitor of [3H]MPP uptake into RCC lines. 
[3H]MPP uptake into high expressing A498 and low expressing ACHN cells. ■ 
hOCT3 expressing cells, □ mock cells. Data are means ± SEM of three 
independent experiments with four repeats each. *** P<0.0001 









































3.3.2 Inhibition of [3H]MPP uptake by cytostatic substances 
 
The interaction of cytostatic substances with hOCT3 was estimated by inhibition 
of [3H] MPP uptake. For our investigation we selected a range of widely used 
cytostatic agents and the results are summarized (Figure 3.9). Several 
independent experiments with quadruplicate determinations showed that 
[3H]MPP uptake was significantly inhibited to 100 µM of melphalan by 40.5 ± 
0.7% (P<0.0001) of the uptake into untreated cells, prednisone to 64.1 ± 4.1% 
(P<0.01), vincristine toy 29.5 ± 1.7% (P<0.0001), irinotecan to 19.6 ± 0.7% 
(P<0.0001). Other substances like doxorubicin, methotrexate, fluoroadenine 
and cyclophosphamide exceeded slight not significant inhibition (P<0.05) of  
[3H]MPP uptake, to 82.2 ± 3.5%, 90.1 ± 3.1%, 77.9 ± 3.1% and 84.5 ± 1.4%, 
respectively, of uptake into untreated cells. Other tested substances such as 

































Fig 3.9 Inhibition of [3H]MPP uptake by different cytostatic agents(100 µM 
each) . □  mock cells,   ■     hOCT3 –expressing cells. All experiments were 
standardized by setting the control (without inhibitor) of each experiment to 
100%. Data are means ±SEM of three independent experiments with four 
repeats each. * P<0.05, ** P<0.01, *** P<0.0001 
 
 
3.3.3 Dixon plot analysis for irinotecan, vincristine, and melphalan 
 
To investigate the type of interaction, selected cytostatic inhibitors (vincristine, 
irinotekan, and melphalan) of [3H]MPP uptake were analyzed by Dixon plots. 
Three experiments were performed for each substance, and shown in Figures 
3.10, 3.11, and 3.12. The Dixon plot analysis showed that all tested compounds 
interact with hOCT3 in an uncompetitive manner. The Ki values for melphalan, 

















































Figure 3.10 Kinetic analysis inhibition of hOCT3 by vincristine. Uptake experiment 
with ● 1 µM and ○ 10 µM [3H]MPP (20 nM [3H]MPP+980 nM MPP or 9980 nM 
MPP) concentrations were performed with different concentration of vincristine. 
Data are presented as Dixon plots. Data are means ± SEM of three repeats. The Ki 




















































Figure 3.11 Kinetic analysis inhibition of hOCT3 for irinotecan. Uptake 
experiment with ● 1 µM and ○ 10 µM [3H]MPP (20 nM [3H]MPP+980 nM MPP or 
9980 nM MPP) concentrations were performed with different concentration of 
irinotecan. Data are presented as Dixon plots. Data are means ± SEM of three 
repeats. The Ki was calculated from these plots.  
Melphalan [µM] 















































Figure 3.12 Kinetic analysis inhibition of hOCT3 for melphalan. Uptake experiment 
with ● 1 µM and ○ 10 µM [3H]MPP (20 nM [3H]MPP+980 nM MPP or 9980 nM 
MPP) concentrations were performed with different concentration of melphalan. 
Data are presented as Dixon plots. Data are means ± SEM of three repeats. The Ki 
was calculated from these plots.  
3.3.4 [3H]MPP uptake into Xenopus laevis oocytes injected with hOCT3 
cRNA 
 
For further investigation of hOCT3 mediated cytostatic transport Xenopus laevis 
oocytes were injected with hOCT3 cRNA. The quality of expression of hOCT3 
was tested by [3H]MPP uptake (Figure 3.13). Injected oocytes took up 1.68 ± 
0.21 pmol [3H]MPP/30min/oocyte. This level was 3 times higher than in H2O 
injected oocytes: 0.56±0.06 pmol [3H]MPP/30min/oocyte (P<0.001). [3H]MPP 
uptake into hOCT3 injected oocytes was inhibited by 100 µM quinine down to a 
level comparable to H2O injected oocytes. Oocytes from the same batch were 
also tested in electrophysiological experiments to show MPP uptake-dependent 
current. However, no currents could be recorded in response to MPP uptake 



































 3Figure 3.13 [ H]MPP uptake into Xenopus laevis oocytes. ■ hOCT3 




3.4. Inhibition of [3H]gemcitabine uptake by nucleoside analogs. 
 
For investigation of [3H]gemcitabine uptake in RCC lines we selected the LN78 
cell line with high expression of hENT1 and hENT2, and the A498 cell line with 
low expression. The [3H]gemcitabine uptakes were inhibited by known 
nucleoside compounds which interact with hENT1 and hENT2 (Figure 3.13). 
LN78 cells showed an almost 3.5 times higher [3H]gemcitabine uptake (359.83 
± 11.3 fmol/5min/106cells) a A498 cells (102.56 ± 6.51 fmol/5min/106 cells). The 
[3H]gemcitabine uptake in LN78 cell line was significantly inhibited by 1 mM 
thymidine to 65.71 ± 14.41 fmol/5min/106 cells, 1 mM cytidine to 92.47 ± 13.74 
fmol/5min/106 cells, 1 µM NBTI to 41.35 ± 4.08 fmol/5min/106 cells, and 1 mM 
gemcitabine to 40.21 ± 1.02 fmol/5min/106 cells of the uptake in the absence of 
added compound. A similar behavior was observed for A498 cells: 1 mM 
thymidine inhibited to 33.90 ± 0.91 fmol/5min/106 cells, 1 mM cytidine to 35.68 ± 
3.16 fmol/5min/106 cells, 1 µM NBTI to 17.98 ± 2.91 fmol/5min/106 cells, and 1 
mM gemcitabine to 18.46 ± 0.60 fmol/5min/106 cells of the uptake in the 
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3Fig. 3.14 Inhibition of [
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H]gemcitabine uptake into RCC lines by known 
hENT’s inhibitors. [3H]gemcitabine uptake into low expressing A498 and high 
expressing LN78 cells. ■ LN78 cell line, □ mean A498 cell line. Data are 
means ± SEM of three independent experiments with four repeats each. ** 
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3.5 Cytostatic sensitivity investigation  
 
3.4.1 Evaluation of the cytotoxic activity of bendamustine and 
chlorambucil by the [3H]thymidine incorporation assay 
 
For the better understanding of the role of OAT1 and OAT3 in the uptake of 
cytostatics and the effects of these drugs on cell proliferation, we performed a 
thymidine incorporation assay in HEK-293 cells stably expressing OAT1 or 
OAT3. For this test, chlorambucil and bendamustine were selected as 
cytostatics because of their structural similarity to specific OAT1 and OAT3 
substrates like p-aminohippurate and estron-3-sulfate, respectively. The most 
important intracellular target of chlorambucil and bendamustine is double-
stranded DNA. Figures 3.15 and 3.16 demonstrate the incorporation of 
radioactive thymidine after 30 min of cytostatic treatment. The result revealed 
that chlorambucil, which is specifically delivered by OAT1, inhibited the 
thymidine incorporation in OAT1 expressing cells with a higher efficiency than in 
OAT3 expressing cells or non-transfected HEK-293 cells. HEK-OAT1 cells 
treated with 10 µM chlorambucil showed a decrease in [3H]thymidine 
incorporation by 30 ± 6%, whereas non-expressing HEK cells and HEK-OAT3 
cells exhibited a smalles decrease by 21 ± 5 (P=0.01) . For 50 µM and 100 µM 
chlorambucil, inhibition of [3H]thymidine incorporation was 45 ± 5% and 40 ± 5% 
(P<0.05) in HEK-OAT1. In mock cells and HEK-OAT3 [3H]thymidine 
incorporation was inhibited 20 ± 5%. When we compared mock and HEK-OAT3 
cells to HEK-OAT1 after chlorambucil treatment, [3H]thymidine incorporation 
was decreased by 25±5% (P<0.05). Bendamustine treatment of OAT3 
expressing cells render a higher inhibition of [3H]thymidine incorporation as 
compared to OAT1 expressing or non-transfected cells. At 10 µM concentration 








































Figure 3.15 [3H ]thymidine incorporation  measurement after chlorambucil treatment. 
Cells were treated 30 min with various concentrations of chlorambucil, ● HEK 293 and 
○ HEK-OAT1 cells, ▼ HEK-OAT3. All experiments were standardized by setting the 
control (without cytostatic) of each experiment to 100%. Data are means ± SEM of 







































Figure 3.16 [3H ]thymidine incorporation  measurement after bendamustine 
 treatment. Cells were treated 30 min with various concentrations of bendamustine, ● 
HEK 293 and ○ HEK-OAT1 cells, ▼ HEK-OAT3. All experiments were standardized 
by setting the control (without cytostatic) of each experiment to 100%. Data are 
means ± SEM of three repeats. * P<0.05, ** P<0.01 
After treatment of HEK-OAT3 cells by 50 µM and 100 µM bendamustine, 
[3H]thymidine incorporation was decreased to 27 ± 6% (P<0.05) and 29 ± 5% 
(P<0.05) compared to non-treated cells. HEK-OAT1 cells showed similar to 
HEK-OAT3 cells a higher sensitivity to bendamustine at a concentration by 10 
µM, [3H]thymidine incorporation was decreased to 24 ± 6% in both HEK-OAT1 
and HEK-OAT3 compared to non-treated. When HEK-OAT1 were treated with 
50 µM bendamustine, they showed increased [3H]thymidine incorporation in 
comparison to HEK-OAT3 . Mock cells (non-transfected HEK-293) at all tested 
concentration were non-sensitive for bendamustine treatment.  
 
3.4.2 Evaluation of the cytostatic activity of melphalan by [3H]thymidine 
incorporation assay. 
 
As melphalan is a widely known DNA damaging agent, its cytotoxic activity was 
measured by [3H]thymidine incorporation assay. Cells were treated with 
different concentrations of melphalan and melphalan together with hOCT 
inhibitors. The results of melphalan treatment are summarized in Figure 3.17. 
We observed that after melphalan treatment [3H]thymidine incorporation with 
CHO-hOCT3 cells was decreased as compared to non-transfected CHO cells in 
a concentration dependent manner. In particular, [3H]thymidine incorporation 
was 10 ± 2% (P<0.05) less upon 10 µM melphalan treatment, 20 ± 6% (P<0.01) 
less with 50 µM melphalan and 35 ± 5% (P<0.01) less with 100 µM melphalan 
as compared to control CHO cells.  
The inhibition of [3H]thymidine incorporation in A498 cells in comparison with 
ACHN cells demonstrated the following values: 35 ± 4% (P<0.01) less 
[3H]thymidine incorporation with 10 µM of melphalan, 30%±5 (P<0.01) less with 
50 µM, and 2% (not significant) less with 100 µM (Figure 3.18). To prove 
hOCT3 mediated melphalan sensitivity both in CHO and RCC cells, we 
incubated them with TEA (Figure 3.19). As it was already demonstrated in 
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previous experiments, CHO-hOCT3 cells possessed more sensitivity to 50 µM 
melphalan as compared to CHO cells. Interestingly, 50 µM melphalan together 
with 2 mM TEA seemed to be more toxic than melphalan alone for CHO, but not 
for CHO-hOCT3 cells. The treatment of CHO-hOCT3 cells with melphalan 
together with TEA led to a recovery for 12 ± 4% (P<0.05) in comparison with 
melphalan treated CHO-hOCT3 cells. Renal carcinoma cells A498 with high 
hOCT3 expression showed a higher sensitivity to melphalan compared to low 
hOCT3 expressing ACHN cells. However, the additional treatments of A498 
with 2 mM TEA lead only to a 5% of recovery (Figure 3.20). 
 
Melphalan [µM]







































Figure 3.17 [3H ]thymidine incorporation  measurement after melphalan treatment of 
CHO cells. Cells were incubated for 30 min with various concentrations of melphalan, ● 
A498 and ○ ACHN cells. All experiments were standardized by setting the control 
(without melphalan) of each experiment to 100%. Data means ± SEM of three repeats.  
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Figure 3.18  [3
 
 
H ]thymidine incorporation after melphalan treatment of RCC cells. The 
cells were incubated for 30 min with various concentrations of melphalan, ● CHO-
hOCT3 and ○ CHO cells,. All experiments were standardized by setting the control 
(without melphalan) of each experiment to 100%. Data means ±SEM of three repeats. * 

















































Figure 3.19 [3H]thymidine incorporation after melphalan/melphalan+TEA treatment in 
CHO cells. Cells were treated with 50 µM melphalan and 5 0µM melphalan together 
with 2 mM TEA for 30 min, ● CHO-hOCT3 and ○ CHO cells. All experiments were 
standardized by setting the control (without melphalan) of each experiment to 100%. 

























































H]thymidine incorporation after melphalan/melphalan+TEA treatment 
in RCC cells. Cells were treated with 50 µM melphalan and 50 µM melphalan 
together with 2 mM TEA for 30 min, ● A498 and ○ ACHN cells. All experiments 
were standardized by setting the control (without melphalan) of each experiment to 
100%. Data means ± SEM of three repeats. ** P<0.01 
3.4.3 Evaluation of cytostatic activity irinotecan and vincristine by the MTT 
assay. 
 
For evaluation of the cytotoxic activity of irinotecan and vincristine we chose the 
MTT assay. The sensitivity of CHO-hOCT3 cells to irinotecan was not 
significantly higher compared to non transfected CHO. However, the irinotecan 
effect on CHO-OCT3 cells was elevated up to 25 ± 3% (P<0.01) upon additional 
treatment with the MDR1-blockator verapamil (Figure 3.21). These decreased 
viability was reversed upon additional treatment of the cells with 500 µM of 
MPP, 2 mM TEA (P<0.01). The decrease in viability in the presence of 500 µM 
MPP, 2 mM TEA, 1 µM verapamil on CHO-hOCT3 cells was less than 7-9% 
and not significant. The viability of CHO-hOCT3 treated by vincristine was 
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inhibited by 40 ± 2.5% (P<0.001), and after verapamil treatment it decreased 
additionally by 19 ± 2.4%. The cytotoxic effect of vincristine can be recovered 
for 15 ± 2.1% (P<0.01) upon 2mM TEA treatment, however the treatment with 
500 µM MPP did not significantly recover viability of treated cells (Figure 3.22).  
The sensitivity of RCC cells to irinotecan and vincristine was also tested by MTT 
assay (Figure 3.23, 3.24). But in contrast to OCT3 stably transfected CHO cells 
irinotecan did not demonstrate a significant difference in viability between A498 
and ACHN cells (Figure 3.23). Renal cancer cells tested by vincristine showed a 
similar behavior as CHO-OCT3 cells. Vincristine treated A498 cells were 18% 
more sensitive to the cytostatic compared to ACHN cells. The effect of 
vincristine was elevated up to 25% by additional treatment with 1µM verapamil. 
The cytotoxic effect of vincristine was slightly rescued by the incubation with 



























Irinotecan - - - - + + + +
MPP - + - - - - + -
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Figure 3.21. Viability test of CHO-hOCT3 cells after irinotecan treatment. The test was 
performed by MTT colorimetric assay. Cells were treated with 100 µM of the cytostatic for 
15 min, washed with PBS and left for additional 24h in the cell culture medium with or 
without 1 µM verapamil.  ■ CHO-hOCT3 and □ CHO cells; Data are means ± SEM of 
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Figure 3.22. Viability test of CHO cells after vincristine treatment. The test was 
performed by MTT colorimetric assay. Cells were treated with 100 µM of the cytostatic 
for  15 min, washed with PBS and left for additional 24h in cell culture medium with or 
without 1µM verapamil. ■ CHO-hOCT3 and □ CHO cells. Data are means ± SEM of 





























Figure 3.23. Viability test of RCC cells after irinotecan treatment. The test was performed 
by MTT colorimetric assay. Cells were treated with 100 µM of the cytostatic for 15 min, 
washed with PBS and left for additional 24h in cell culture medium with or without 1 µM 
verapamil.  ■  A498 and □ ACHN cells. Data means ± SEM of three repeats. ** P<0.01, *** 
P<0.001 
rinotecan - - - - + + + +
MPP - + - - - - + -
TEA - - + - - - - +
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Figure 3.24. Viability test of RCC cells after vincristine treatment. The test was 
performed by MTT colorimetric assay. Cells were treated with 100 µM of the cytostatic 
for 15 min, washed with PBS and left for additional 24 h in cell culture medium with or 
without 1 µM verapamil. ■  A498 and □ ACHN cells. Data are means ± SEM of three 











3.4.4 Evaluation of the cytostatic activity of gemcitabine by MTT assay. 
 
To prove that cytotoxic sensitivity related to hENT1 and hENT2 activities we 
performed investigations on high expressing LN78 and low expressing A498 
cells (data presented in figures 3.25). Cells were incubated with 100 µM 
gemcitabine for 15 min and different combinations of ENT1 and 2 inhibitors. 
After incubation cells were washed and left for 24 h to maximize effects. The 
viability of LN78 cells were inhibited by gemcitabine to 14.36 ± 5.93% as 
compared to non-treated cells. A498 cells were inhibited by gemcitabine to 
50.38 ± 3.35%. The gemcitabine effect was slightly reversed by addition of 1 
mM thymidine or 1 mM cytidine to LN78 cells: 28.99 ± 2.25% and 31.14 ± 
4.91%. A similar behavior was observed with A498 cells: 40.19 ± 2.73% and 
39.46 ± 2.60%. The strongest reversal was obtained when cells were incubated 
with gemcitabine together with 500 µM NBTI. Viability of LN78 cell line was 
77.90 ± 6.71% almost 5 times higher than cells incubated with gemcitabine 
incubation alone. The viability of A498 cells was decreased after incubation with 
gemcitabine together with 500 µM NBTI to 65.63 ± 2.63%. LN78 and A498 cell 
lines were incubated with 500 µM NBTI alone. The viability of LN78 cells were 





































Figure 3.25. Viability test of RCC cells after gemcitabine treatment. The test 







the cytostatic for  15 min, washed with PBS and left for additional 24h. ■  











 4. Discussion 
 
The resistance of tumour cells to cytostatic drugs represents a large and 
unfortunately often insurmountable problem in the chemotherapy. The 
increased expression of cytostatic drug exporting transporters like the multidrug 
resistant transporter MDR and multidrug resistance related proteins (MRP) are 
considered a substantial cause for the cytostatic drug resistance. While these 
exporting transporters have been well examined over the last decade very little 
is known about transporters, which could lead to an increased uptake of 
cytostatic drugs in tumor cells. First of all, only to some extent it has been 
examined, which of the well-known, to the SLC (carrier solute) family belonging 
uptake transporters are expressed in kidney tumor cells. Second, the individual 
equipment of tumor cells with uptake transporters was so far not explored 
systematically. Third, little is known about the interaction of cytostatics with 
several uptake transporters of the SLC family. Therefore the aim of this study 
was firstly to examine the expression level of thirty well characterised uptake 
transporters of the SLC family in kidney tumour cells, secondly to investigate 
the interaction of transporter proteins with several clinical relevant cytostatics, 
and thirdly to find out the role of the uptake transporters in the cytostatic effect 
and the proliferation of the tumour cells.   
  
4.1 Expression of uptake transporters of the SLC family in kidney 
tumour cells  
 
Initially several primers were designed on the base of the DNA sequence of the 
transporters from the NCBI Database. To consider the splice variants of each 
transporter by the selection of the primers we used the conserved regions of the 
DNA sequence.  From 5 different kidney tumor cell lines the total RNA was 
purified and after reverse transcription were PCR-products generated which 
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observed a similar size (as indicated in the tables 2.1-2.8). The PCR-products 
were cloned and sequence verified. These clones were then used as a 
standard for the quantitative resolution of the expression level of each 
transporter by real-time PCR with SYBR Green I.   
As a target for cytostatic drugs we examined the expression level of organic 
anion transporters in the kidney tumor cell lines 786-O, RCCNG1, A498, LN78, 
ACHN and tumor as well as normal tissue from the same patient. Organic anion 
transporters (OAT) are mainly expressed in the epithelial cells of kidney 
proximal tubules, but also in liver and blood-brain barrier. The substrates for 
these transporters include organic anions, such as p-aminohippurate (PAH) and 
estrone sulfate (ES) [8]. OAT family members (OAT1, OAT2, OAT3, OAT4, and 
URAT1) are very important for excretion of organic anions from blood to urine 
[106]. They are also involved in the reabsorption of endogenous organic anions 
like estrone sulfate, dehydroepiandesterone sulfate (DHEAS) and urate from 
primary urine through the luminally located OAT4 and URAT1 [106]. Nothing 
was known about the expression of OATs in kidney tumor cells and little about 
the interaction of cytostatics with organic anion transporters. Up to now only the 
interaction of methotrexate with organic anion transporters was reported [107]. 
There are some anionic cytostatics which are used in chemotherapy of cancer 
patients, e.g. chlorambucil and bendamustin. Unpublished studies in our 
department demonstrated the interaction of chlorambucil and bendamustin with 
OAT1, OAT3, and OAT4 (Dr. Yohannes Hagos personal communication). On 
the other hand, the use of cytostatics in the cancer treatment may cause an 
accumulation of these drugs in the kidney proximal tubule cells and result in 
complications like nephropathy [108]. Our study revealed unfortunately no or 
only little expression of organic anion transporters in kidney cancer cell lines 
and tumour tissue in comparison to a normal kidney tissue. Therefore organic 
anion transporters are not the appropriate target transporter protein for 
chemotherapy of RCC with anionic cytostatics.   
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Organic cation transporters (OCT) also belong to the SLC22 family. The OCT 
transporters are mostly expressed in kidney, liver and blood-brain barrier [68]. 
These transporters possess an affinity for positively charged endogenous 
(epinephrine, norepinephrine, carnitine etc.) and exogenous substances (MPP, 
TEA ) [68]. Also it was shown that OCTs play an important role in the drug 
distribution in the organism [9] and drug transport from blood to brain [109]. 
Concerning the cytostatic drug transport, it is known, that OCT2 is responsible 
for cisplatin accumulation inside the kidney and brain tissues [11]. 
Nephropathies and neuropathies have been observed after chemotherapy with 
cisplatin due to accumulation of this cytostatic [110, 111].  
The results of this study show that OCT3 is the only OCT family member that 
was expressed in some kidney cancer cell lines. In the kidney tumor tissue from 
a patient OCT2 was also highly expressed. This fact renders OCT2 and OCT3 
appropriate candidates to be considered in kidney tumor therapy. Kidney tumor 
as well as normal tissue and the cell lines A498 and ACHN exhibited a very low 
expression of OCT6. This transporter was previously described as a transporter 
of doxorubicin [12].  
Taken together, OCTs expressed in renal tumor tissues may be used to target 
cationic cytostatics. Additional experiments were required to show an increased 
sensitivity of OCT-expressing cells to cytostatics. 
The organic anion transporting polypeptides are highly present in the liver, but 
some of the OATP family members like OATP-A, OATP-D and OATP-E [9] are 
also expressed in kidneys. These proteins transport organic anions such as 
taurocholate, estrone sulfate, but possess additionally the affinity to bile acids 
[112, 113]. As previously described, several OATPs showed an interaction with 
cytostatics like bamet-UD2 (a cisplatin bile acid derivate) and irinotekan 
metabolites [9, 13, 17].  Therefore OATPs are further candidates to be included 
in our study as potential transporters for cytostatics in tumor cells. The results 
demonstrate a high expression of OATP-A and OATP-B in tumor kidney tissue 
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and in some of the kidney cancer cell lines. The presence of these transporters 
could be used to deliver special cytostatics to the tumor cells. 
Nucleoside transport in humans is provided by concentrative and equilibrative 
nucleoside transporters. CNTs and ENTs are ubiquitously expressed in different 
parts of human body [18, 114]. These group of transporters posses a high 
affinity to nucleosides. Many of the new cytostatic drugs are nucleoside 
analogs, such as  5’-fluorouracil, uramustine and gemcitabine [20], [19]. These 
facts could be used to treat kidney cancer cells with nucleoside analogs like 
gemcitabine. In our study a clear cut expression profile was observed in the 
kidney tumor cell lines and tumor as well as normal tissue. In most of the 
examined cells the expression of ENTs was much higher than the expression of 
CNTs. That is why ENTs are very interesting transporters for the developing an 
ENT-based strategy of chemotherapy for kidney tumor cells.   
The L-type amino acid transporters are ubiquitously expressed in human 
organism. Besides transporting  L-type  neutral amino acids, LATs handle 
melphalan, a frequently used cytostatic in chronic lymphatic leukemia [115, 
116]. Previously it was reported that LAT1 is expressed in lymphoma cells [35]. 
Because of high expression of LATs in the kidney, it was important to observe 
the expression pattern of the malignantly transformed kidney cells. The RT-PCR 
analysis demonstrated that in the kidney tumor tissue the expression level of 
LATs was the same as in normal tissue. This suggests that renal cancer cells 
may be sensitive to cytostatic analogs of L-amino acids. 
The sodium dicarboxylate transporter (NaDC3) is highly expressed in kidney, 
liver, brain and placenta. Nothing is known concerning its interaction with 
cytostatics and about the expression in tumor cells. The physiological function 
of NaDC3 is the supply of epithelial cells with Krebs-cycle metabolites such as 
succinate or α-ketoglutarate [10, 68, 117]. In kidney cancer cell lines and in 
tumor tissue, the expression of NaDC3 was very high. Possibly, this transporter 
may have an important metabolic function in delivering in Krebs cycle 
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metabolites to cancer cells. Therefore it could be a very interesting target by the 
decreasing the supply of dicarboxylate delivery and limitation of the energy 
generation of the tumor cell.      
Members of the monocarboxylate transporter (MCT) family are ubiquitously 
expressed in the human body [25, 26, 118, 119].  The most important function 
of MCTs is the distribution of monocarboxylate such as lactate, and  pyruvate to 
the target cells [25-27, 120, 121]. Furthermore, members of the MCT family 
(MCT-2) showed an interaction with ifosfamide metabolites as demonstrated 
previously [27]. The specific cytostatic transport and the interaction of the MCTs 
with some of the cytostatics make them very important transporters to be 
considered in chemotherapy. However, our expression study revealed a very 
high expression of the MCTs in healthy tissue as well as in tumor tissue.  This 
data suggest that MCT transporter is important for the survival of all cells. This 
fact makes it difficult to consider these transporters for tumor-specific 
chemotherapy. 
The SLC19 is widely expressed in the human organism. This group of 
transporters which have affinity for reduced folate/thiamine, was interesting for 
us as a potent transporter of cytostatic drugs like methotrexate [122]. In kidney 
tumor cell lines and normal tissue the thiamine transporter ThTr as well as the 
reduced folate transporter (RFT) was observed middle expression level. In 
some RCC cells, RFT, as well as ThTr, showed lower expression levels 
compared to normal tissues. Thus, the choice of chemotherapy with folate-
derived cytostatics in this case may rather result in major side effects, then in 
efficient anticancer treatment.   
Nowadays a lot of attention is paid to efflux transporters from ABC family. The 
ABC transporters are widely distributed in human tissue. In the kidney a few 
members of the ABC family like MRP1, MRP2, MRP4, and MDR1 are highly  
expressed  [123], 26]. They use ATP for pumping several chemicals such as 
cytostatics and other compounds out of the cell [25,124]. Physiologically these 
115 
 
transporters pump out endogenous “waste“, glutathione conjugates and 
glucoronides, and exogenous hydrophobic xenobiotic like benzapyrenes  [125].  
The functions of ABC transporters include of course  the excretion of cytostatics 
from cancer cells [126], which renders tumor cells chemoresistant. We 
performed in kidney cancer cell lines and tumor tissues a screening of the ABC 
transporter family to compare the level of the expression with the expression of 
the SLC family members. Most of the tested ABC transporters were highly 
expressed. It will be very important in the planning of chemotherapy to consider 
the expression level of the ABC transporters, because as efflux transporters 
they counteract of the uptake transporter.  
 
4.2 Real-time PCR reinvestigation of SLC22 transporters in renal 
carcinoma cells 
 
As mentioned before the SLC22 transporters play an important role in transport 
organic anions and cations in human body. This makes the SLC22 group also 
important for transport of wide range of cytostatics. We showed previously the 
expression of OAT1 and OCT3 in our tested cell lines. To evaluate differences 
in expression we used the TaqMan real-time PCR method. We found that OAT 
transporters are present at low levels in comparison to OCT3. For further 
experiments we chose the OCT3 expressing cell line A498 and the non-
expressing ACHN line.  
A similar procedure we used for investigation of ENT transporters in kidney 
carcinoma cell lines. We tested by TaqMan real-time PCR the expression levels 
in LN78 and A498. For further experiments we used the high expressing LN78 
cell line ENT1, 2 and the low expressing A498.  
 
 
4.3 Investigation of OCT3 activity in renal carcinoma cell lines  
 
Human OCT3 has a high affinity for cationic substrates such as MPP, 
histamine, cimetidine, and quinine. It was shown that OCT1, OCT2, and OCT3 
were inhibitable by quinine. The IC50 value for quinine is 5 nM [53]. All members 
of the OCT family also transported TEA, but with different affinity. Data of the 
interaction of organic cation transporters with cationic substances are 
summarized in figure 4.1    
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Figure 4.1 Structural formula of substrates transported by OCTs 





To prove the presence of OCT3 in tumor cell membranes we performed a 
series of uptake experiments with known OCT3 substrates. We found that 
[3H]MPP was transported in high expressing A498 cells with a similar rate as in 
CHO cells stably transfected with OCT3. The ability to transport MPP with 
similar affinity was shown for OCT1, OCT2 and OCT3 [127]. To clarify the 
organic cation transport activity in renal carcinoma cells we inhibited [3H]MPP 
uptake by tetraethylammonium (TEA). Organic cation transporter 1 and 2 
showed high affinity to TEA in comparison to organic cation transporter 3 [59]. 
The A498 cell line expressing high amounts of OCT3 showed a similar profile of 
[3H]MPP uptake inhibition by TEA as CHO cells stably transfected with OCT3. 
Therefore, we suggest is that organic cation transport in A498 cells is mediated 
by OCT3. The low expressing ACHN cells did not show significant uptake of 
[3H]MPP and no inhibition by TEA.   
 
4.4 Investigation the interaction of cytostatics with OCT3  
 
The main function of human OCT3 was connected with the transport of 
physiologically active substances such as adrenaline, noradrenaline, and 
histamine [128]. The impact of OCT3 on transport of cytostatics was not clear. It 
was shown that OCT3 can transport a number of platinum compounds such as 
carboplatin and oxaliplatin [54]. We performed a number of [3H]MPP uptake 
experiments to test for cytostatics which may be transported by OCT3. For our 
experiments we selected substances with structural similarity to OCT3 
substrates. Among these compound, irinotecan, vincristine, and melphalan 
inhibited [3H]MPP uptake by more than 50%. 
The inhibitory cytostatics were tested in competitive inhibition experiments to 
investigate their affinity and character of interaction with OCT3. After data 
analysis by Dixon plots it was found that irinotecan, vincristine and melphalan 
interact with OCT3 in a non-competitive manner.  Dixon plots also provided the 
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possibility to calculate the affinity i.e. the Ki value of interaction. It was found 
that irinotecan and vincristine interacted with high affinity showing Ki value of 
1.75 µM and 17 µM, respectively. Melphalan exhibited a medium affinity: 
Ki=366 µM. The obtained results suggest that the tested substances cannot 
occupy the substrate recognition centre and cannot be transported. However, 
deviations from the classical competitive type of inhibition were also observed 
for some pairs of substrate and inhibitors (Koepsell H., unpublished data) [59]. 
From this point of view we cannot exclude that the tested cytostatics are 
transported by OCT3.  
 
 4.5 Investigation on the activity of ENTs in renal carcinoma cell 
lines 
 
Equilibrative nucleoside transporters are widely expressed in human body [21]. 
Special functions of ENTs are exchanges of nucleoside analogs. Renal 
carcinoma cell lines were found to have high expression levels of ENT 1 and 2 
in comparison to concentrative nucleoside transporters (CNT). The expression 
profiles suggest that nucleoside transport is mainly dependent on ENT 1 and 2. 
It was shown that ENT1 prefers as substrates purine analogs such as guanine 
and adenosine [81]. ENT2 mainly transports pyrimidine analogs such as 
citydine and thymidine [129]. Both transporters have high affinity to NBTI which 
is used as inhibitor for ENT transporters. Also both ENT1 and 2 interact with a 
number of cytostatics such as gemcitabine and cladribine [20]. Substrates 
which interact with ENT1 and 2 are shown in figure 4.2. To investigate the 
correlation between expression and activity of equilibrative nucleoside 
transporters we performed a series of uptake experiments with [3H]gemcitabine. 
For uptake experiments were chosen the LN78 cell line expressing high 
amounts of ENT1 and 2 and the A498 low expressing cell line.  [3H]gemcitabine  
uptake was inhibited by thymidine, cytidine, and NBTI. The inhibition profile 
suggested that nucleoside transport in LN78 cells is mediated by ENT1 and 2. 
Thus, renal carcinoma cells expressing high amounts of ENT1 and 2 may be 
















Figure 4.2 Substrates interacting with ENT1 and 2. A – adenosine,                     
B – thymidine, C – NBTI, D - gemcitabine  
 
4.6 Transporter-mediated inhibition of thymidine incorporation by 
chlorambucil, bendamustin and melphalan  
 
Finally, as a proof of principle, I tested whether the expression of a transporter 
influences cell growth in the presence of a cytostatic. [3H]thymidine 





cytostatics. The test was performed on HEK293 cells stably expressing either 
human OAT1 or human OAT3. Since these two transporters interact with 
organic anions, I chose the anionic cytostatics bendamustin and chlorambucil, 
both alkylating nitrogen mustard compounds. In OAT3-expressing cells the 
[3H]thymidine incorporation was somewhat more inhibited by bendamustin than 
in OAT1-expressing cells, and in both cells slightly more than  in mock cells. 
These results suggest that the expression of OAT1 and OAT3 renders cells 
slightly more susceptible to bendamustine. Chlorambucil, on the other hand, 
inhibited [3H]thymidine incorporation considerably more in OAT1-expressing 
cells than in mock cells and OAT3-expressing cells. Thus, OAT1 makes cells 
more sensitive to chlorambucil.  
To evaluate the cytotoxic effect of melphalan on OCT3 expressing cells we also 
chose [3H]thymidine incorporation as a method. After uptake of melphalan into 
cells it binds to –NH2 and -SH groups of proteins or nucleic acids [130]. It was 
shown that the mustard residue interacts with the γ-phosphate group of 
nucleoside triphosphates and produces mustard-nucleoside derivates with 
possess toxic effects [131]. OCT3 expressing CHO cells showed a correlation 
between melphalan concentration and the inhibition of [3H]thymidine 
incorporation. To prove that the cytotoxic effect of melphalan is dependent an 
OCT3 activity we inhibited melphalan uptake by 2 mM of TEA. OCT3 
expressing cells which were treated by a combination of melphalan and TEA 
showed less inhibition of [3H]thymidine incorporation  in comparison to those 
treated with only melphalan.  
To test the possibility that melphalan can be used for treatment renal 
carcinomas expressing OCT3, we performed similar experiments with renal 
carcinoma cell lines. From my previous investigations on expression and 
function of OCT3 in RCC lines I selected A498 with high expression of OCT3 
and ACHN as a non-expressing cell line. Both cell lines were also tested for the 
expression of the L-amino acid transporters 1 and 2 which mediate melphalan 
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uptake. A498 and ACHN cell lines showed high expression levels for LAT1 and 
low expression levels for LAT2. 
Melphalan sensitivity tests revealed that A498 cells are more sensitive than 
ACHN, but sensitivity was observed for higher melphalan concentration. At high 
melphalan concentrations, both cell lines showed similar [3H]thymidine 
incorporation. We suggest that the sensitivity to melphalan is dependent on two 
transporter system, OCT3 and LAT1, which work independently. OCT3 can 
transport at low concentrations of melphalan with high efficiency, whereas LAT1 
contributed at high concentrations of melphalan. The cytotoxic effect of 
melphalan was not significantly inhibited by TEA. This phenomenon can be 
explained by melphalan transport by LAT1 which is not inhibited by TEA.      
 
4.7 Transporter mediated-cytotoxic activity of irinotecan 
    
Irinotecan was obtained by modification of SN38 (camptotecin) which is a 
strong inhibitor of topoisomerase I. This cytostatic is used for the treatment of 
the colorectal cancer as part of the cytostatics combination FOLFIRI [132]. On 
the other hand it was shown that the expression of OCT3 is present in many 
tested colorectal cancer samples [11]. Topoisomerase I plays an important role 
in cell cycle and relaxed secondary structures of DNA [97]. In general, 
topoisomerase I activity is important for gene translation [133]. SN38 inactivates 
topoisomerase I and the enzyme is locked on DNA. [100]. The formed 
complexes are blocking DNA duplication and RNA translation.  The SN38 
treatment inhibits the expression of many genes and makes cells more sensitive 
to other cytostatics. Irinotecan is a positively charged substance which has a 
partial structural similarity to MPP. After transport into the cell, irinotecan is 
converted to SN38 by hydrolysis. SN38 is inactivated by glucoronidation [97]. 
Irinotecan cytotoxic activity is dependent on the concentration of the active 
SN38 product inside the cells. The concentration of SN38 is dependent on 
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activities of hydrolase, UDP-glucuronosyltransferase, and MDR1, which export 
SN38. I tried to investigate the role of OCT3 and MDR1 on irinotecan 
cytotoxicity and I used a combination of irinotecan with verapamil. Verapamil is 
a potent inhibitor of MDR1 [134]. MDR1 expression was detected in CHO cells. 
It was found that CHO stably expressing OCT3 cells treated irinotecan and 
verapamil had a lower viability in comparison to non-expressing CHO cells 
treated only with irinotecan. This proves the importance of MDR1 for 
chemoresistancy to irinotecan [135]. But the renal carcinoma cell line A498 with 
high expression of OCT3 was not significantly inhibited by irinotecan in 
comparison to non-expressing ACHN cell line.  As mentioned before, cytotoxic 
activity of irinotecan is dependent a three processes. Possibly, UDP-
glucuronosyltransferase activity was higher in RCC lines in comparison to CHO 
cells.  
 
4.8 Transporter mediated cytotoxic activity of vincristine 
 
Vincristine is a potent cytostatic which is used for the treatment of blood 
cancers such as non Hodgkin’s lymphoma, and lymphoblastic leukemia [136-
138]. The main intracellular target for vincristine is the mitotic spindle included in 
their structure tubulin. Vincristine binds to tubulin molecules and prevents their 
polymerization.  After vincristine treatment, cells cannot divide and this lead to 
cell death by apoptosis or to producing artificial caryotypes [139, 140]. 
Vincristine possesses a weak positive charge and can be transported by OCT3. 
From my data I suggest that vincristine is more toxic in comparison to irinotecan 
and melphalan. A possible reason is the high affinity to tubulin, the resulting 
complexes have a low constant of dissociation. After treatment, cells cannot 
excrete or metabolize bound to tubulin vincristine, one way for surviving is 
exchange of affected tubulin molecules by de novo protein synthesis. Additional 
treatment vincristine with verapamil amplified the cytotoxic effect of vincristine. 
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This cytostatic effect was only slightly reversed by inhibitors of OCT3. This 
finding suggests that even low amounts of vincristine disturb the microtubule net 
an irreversible, manner. One pronouncing side effect of vincristine is neuropathy 
[141]. This side effect could be due to OCT3 mediated transport, since OCT3 is 
expressed in the central neural system. 
 
4.9 Conclusions and outlook 
 
In the presence study I investigate of the dependence of cytostatic activities on 
influx transporters expressed in renal carcinoma cell lines. These cell lines 
exhibited a variable profile of influx and efflux transporters. For example I found 
that the expression of tissue-specific transporters such as OAT1, OAT2, OAT3, 
OCT1 and OCT2 was decreased. In three out of five tested RCC lines, a high 
expression of the organic cation transporter 3 was observed. These results 
allow for the following conclusions. First, we cannot treat renal carcinomas by 
cytostatics which interact with OATs such as chlorambucil, bendamustin and 
methotrexate. Second, expression of OCT3 gives the possibility to select 
specific cytostatics which are transported by OCT3. Third, I found an interaction 
of irinotecan, melphalan and vincristine with OCT3. These cytostatics can be 
used for the treatment of renal carcinomas. On other hand, the presence of 
efflux transporters like MDR1 and MRPs make tumor cells chemoresistant. 
Inhibitors of multidrug transporters can be used to overcome chemoresistance. 
But this treatment may produce side effects in normal tissues.  
Since under the therapy a selection pressure is produced, tumor cells with yet 
another set of transporters may arise and expand. Hence, a re-testing of 
transporter expression may be needed before applying cytostatic therapy.  
Taken together I have provided evidence for the expression of a number of 
transporters in renal carcinoma cells. Some of these transporters may be used 
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to target cytostatic drugs to the cancer cells and to partially overcome the 
chemoresistance. The next experiments to be performed will therefore test of 
the influence of cytostatics selected on the basis of transporter expression. I 
hope that in the future a tailored therapy can be delineated from transporter 
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 Addition 1 
 
Symbol Alias Function  Expression Mendelian 
disease 
ABCA ABCA1 ABC1 Cholesterol efflux 
into HDL 
ubiquitous Tangier disease, 
FHDLD 









RP, CRD, CD 
 ABCA5   Muscle, heart, 
testes 
 
ABCA6   Liver  
ABCA7    Spleen, thymus  
ABCA8   Ovary  
ABCA9   Heart  
ABCA10   Muscle, heart  
ABCA12   Stomach  
ABCA 13   Ovary, kidney, 
thymus 
 
ABCA17P   ubiquitous   








ABCB2 TAP1 Peptide transport All cells Immune deficiency 
ABCB3 TAP2 Peptide transport All cells Immune deficiency 
ABCB4 PGY3 PC transport Liver PFIC3 
140 
 
ABCB5   ubiquitous  
ABCB6 MTABC3 Iron transport, 
Fe/S transport 
Mitochondria  
ABCB7 ABC7  Mitochondria XLSA/A 
ABCB8 MABC1  Mitochondria  
ABCB9   Heart, brain  
ABCB10 MTABC2  Mitochondria  
ABCB11 SPGP Bile salt transport Liver PFIC2 
ABCC ABCC1 MRP1 Drug resistance  Lung, testes  




ABCC3  MRP3 Drug resistance Lung, intestine, 
liver 
 
ABCC4  MRP4 Nucleoside 
transport 
Prostate  
ABCC5 MRP5 Nucleoside 
transport 
Ubiquitous   
ABCC6 MRP6  Kidney, liver Pseudoxantoma 
elasticum 
ABCC7  CFTR Chloride ion 
channel 
Exocrine tissue Cystic Fibrosis, 
CBAVD 
ABCC8 SUR Sulphonylurea 
receptor 
Pancreas FPHHI 
ABCC9 SUR2 K(ATP)channel 
regulation 
Heart, muscle  
ABCC10 MRP7  Low in all tissues  
ABCC11   Low in all tissues  
ABCC12   Low in all tissues  
141 
 





 Peroxisomes  
ABCD3 PXMP1, 
PMP70 
 Peroxisomes  
ABCD4 PMP69, 
P70R 
 Peroxisomes  







ABCF ABCF1 ABC50  Ubiquitous  
ABCF2   Ubiquitous  
ABCF3   Ubiquitous  












ABCG4 White2  Liver  
ABCG5 White3 Sterol transport Liver, intestine Sitosterolemia 
ABCG8  Sterol transport Liver, intestine Sitosterolemia 
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